

BBC Chronic Pain Survey

Fieldwork: Wednesday 9th - Monday 14th March 2022

| Table Names | Table Filters |
|--|---|
| 0001 D1. Do you have any physical or mental health conditions or illnesses lasting or expected to last for 12 months or more? | All adults aged 16-75 in the UK |
| 0002 Q1. How is your health in general? Would you say it is... | All adults aged 16-75 in the UK |
| 0003 Q2. Throughout our lives, most of us have had pain from time to time (such as minor headaches, sprains, and toothaches). In the last 12 months, have you had pain other than these everyday kinds of pain? | All adults aged 16-75 in the UK |
| 0004 Q3. In the last 12 months, have you personally experienced any chronic pain, that is pain that has lasted longer than three months? | All experienced Pain in the past 12 months |
| 0005 Q4. And how often do you currently experience chronic pain? | All experienced chronic pain in past 12 months |
| 0006 Q4. And how often do you currently experience chronic pain? (rebased to include all respondents) | All adults aged 16-75 in the UK |
| 0007 Q5. Thinking about this chronic pain, which one of the following statements most closely reflects your experience? | All who currently experience chronic pain |
| 0008 Q5B. Which, if any, of the following types of activity would you say are impacted by your chronic pain? If there are no specific activities which you feel are impacted by this chronic pain, please choose the "None" option | All with activity-limiting chronic pain |
| 0009 Q6. On balance, which, if any, of the following statements BEST describes the extent to which you are able to cope with this chronic pain, day-to-day? | All who currently experience chronic pain |
| 0010 Q7. Have you had any direct contact with a healthcare professional for this chronic pain in the last 12 months? | All who currently experience chronic pain |
| 0011 Q8. Has a healthcare professional given you a formal diagnosis of the cause of this chronic pain? | All who currently experience chronic pain |
| 0012 Q9. And which of the following diagnoses did you receive from a healthcare professional in relation to this chronic pain, or was it something else? | All with diagnosis of their chronic pain |
| 0013 Q10. Which, if any, types of treatment are you currently taking/ receiving for this chronic pain? | All who currently experience chronic pain |
| 0014 Q11. You mentioned that you are currently taking opioids for this chronic pain. Which of the following opioids (or types of opioid) are you currently taking? | All currently taking opioids for chronic pain |
| 0015 Q12. You mentioned that you are currently taking opioids for this chronic pain. When did you first start taking them? | All currently taking opioids for chronic pain |
| 0016 Q13. During the course of this chronic pain, you may have had contact with one or more healthcare professionals about your chronic pain. Thinking about all of the care that you have received from the health care professionals for this chronic pain, how would you rate it overall? | All with chronic pain and had contact with health professional (past 12 months) |
| 0017 Q14. And are you currently on a waiting list to start treatment, or booked in but yet to start any of the following treatments for this chronic pain? | All who currently experience chronic pain |
| 0018 Q15. Thinking about the treatment or treatments that you are waiting to start that relates to your chronic pain, for how long have you been waiting? - Summary | All awaiting treatment for chronic pain |
| 0019 Q15. Thinking about the treatment or treatments that you are waiting to start that relates to your chronic pain, for how long have you been waiting? - Surgery | All awaiting treatment for chronic pain |
| 0020 Q15. Thinking about the treatment or treatments that you are waiting to start that relates to your chronic pain, for how long have you been waiting? - Pain management programme | All awaiting treatment for chronic pain |
| 0021 Q15. Thinking about the treatment or treatments that you are waiting to start that relates to your chronic pain, for how long have you been waiting? - Opioid withdrawal programme | All awaiting treatment for chronic pain |
| 0022 Q15. Thinking about the treatment or treatments that you are waiting to start that relates to your chronic pain, for how long have you been waiting? - Other – i.e. I'm waiting for another type of treatment | All awaiting treatment for chronic pain |
| 0023 Sample Profile | All adults aged 16-75 in the UK |

21-087515-10 - 9th March 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

D1. Do you have any physical or mental health conditions or illnesses lasting or expected to last for 12 months or more?

All adults aged 16-75 in the UK

| | Gender | | | Age | | | | | Social Grade | | | | Region | | | | | | | | | | | |
|--|-------------|-------------|-------------|------------------|------------------|-------------------|-------------------|------------------|-----------------|-----------------|-----------------|------------------|------------|----------------|---------------------------|---------------|---------------|-----------------|-----------------|------------|----------------|--------------|------------|------------------|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | AB | C1 | C2 | DE | North East | North West | Yorkshire and Humbersid e | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 4435 | 2127 | 2280 | 673 | 776 | 793 | 861 | 1332 | 1948 | 1369 | 415 | 703 | 184 | 500 | 376 | 396 | 325 | 416 | 359 | 564 | 601 | 215 | 379 | 120 |
| Weighted base | 4435 | 2183 | 2224 | 661 | 817 | 757 | 814 | 1386 | 1182 | 1301 | 950 | 1002 | 176 | 485 | 366 | 389 | 323 | 410 | 373 | 603 | 605 | 209 | 374 | 124 |
| Yes - reduces my ability to carry out day-to-day activities a lot | 360 8% | 170 8% | 187 8% | 60 9% G | 70 9% | 58 8% | 48 6% | 124 9% G | 89 7% | 82 6% | 47 5% | 143 14% UK | 17 9% | 33 7% | 37 10% | 34 9% | 25 8% | 43 10% | 24 6% | 50 8% | 45 8% | 12 6% | 27 7% | 13 10% * |
| Yes - reduces my ability to carry out day-to-day activities a little | 693 16% | 335 15% | 348 16% | 124 19% FG | 139 17% FG | 90 12% | 106 13% | 235 17% FG | 165 14% | 203 16% | 125 13% | 199 20% UK | 25 14% | 90 18% O | 45 12% | 55 14% | 59 18% | 60 15% | 60 16% | 87 14% | 93 15% | 34 17% | 67 18% | 17 14% * |
| Yes – although does not reduce my ability to carry out day-to-day activities | 688 16% | 349 16% | 336 15% | 115 17% F | 122 15% | 90 12% | 119 15% | 243 17% F | 188 16% | 201 15% | 167 18% L | 131 13% | 28 16% | 71 15% | 61 17% | 58 15% | 49 15% | 50 12% | 75 20% RU | 98 16% | 85 14% | 30 14% | 64 17% | 20 16% * |
| No – I have no physical or mental health conditions or illnesses lasting or expected to last for 12 months or more | 2566 58% | 1264 58% | 1291 58% | 329 50% | 459 56% D | 499 66% DEH | 519 64% DEH | 760 55% | 713 60% L | 784 60% L | 580 61% L | 489 49% | 101 58% | 285 59% | 209 57% | 225 58% | 181 56% | 251 61% | 200 54% | 351 58% | 362 60% | 125 60% | 203 54% | 72 58% * |
| Don't know | 48 1% | 28 1% | 19 1% | 14 2% H | 9 1% H | 11 1% | 7 1% | 6 * | 6 1% | 13 1% | 14 1% | 14 1% I | 1 * | 3 1% | 4 1% | 5 1% | 1 * | 2 1% | 9 3% NQR | 9 2% | 8 1% | 1 1% | 4 1% | - - * |
| Prefer not to say | 81 2% | 37 2% | 42 2% | 19 3% H | 18 2% | 9 1% | 16 2% | 19 1% | 20 2% | 18 1% | 17 2% | 25 3% | 4 2% | 3 1% | 9 3% N | 12 3% N | 8 2% | 4 1% | 4 1% | 8 1% | 11 2% | 6 3% N | 9 2% | 2 2% * |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|--------------------------------|-------------|------------|------------|------------------|------------------|------------|------------|------------------|------------|------------|------------|------------------|-----------|------------|------------|------------|------------|------------|------------|------------|------------|-----------|------------|----------------|
| NET: Yes (day-to-day impacted) | 1053 24% | 505 23% | 536 24% | 184 28% FG | 209 26% FG | 147 19% | 154 19% | 358 26% FG | 254 21% | 284 22% | 172 18% | 342 34% UK | 42 24% | 123 25% | 83 23% | 89 23% | 84 26% | 102 25% | 85 23% | 137 23% | 138 23% | 47 22% | 94 25% | 30 24% * |
| NET: Yes (any) | 1741 39% | 854 39% | 872 39% | 299 45% FG | 330 40% FG | 237 31% | 273 34% | 601 43% FG | 442 37% | 486 37% | 339 36% | 473 47% UK | 70 40% | 194 40% | 143 39% | 147 38% | 133 41% | 152 37% | 159 43% | 235 39% | 223 37% | 77 37% | 158 42% | 50 40% * |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions (5%): A,B/C,D/E/F/G,H,I/J/K,L,M/N/O/P/Q/R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)

ColumnMeans (5%): A,B/C,D/E/F/G,H,I/J/K,L,M/N/O/P/Q/R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)

21-087515-10 - 9th March 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q1. How is your health in general? Would you say it is...

All adults aged 16-75 in the UK

| | Gender | | | Age | | | | | Social Grade | | | | Region | | | | | | | | | | | |
|-------------------|-------------|-------------|-------------|------------------|------------------|------------------|-----------------|------------------|-------------------|-----------------|------------------|------------------|---------------|-----------------|--------------------------|-----------------|-----------------|-----------------|------------|------------|----------------|------------|--------------|------------------|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | AB | C1 | C2 | DE | North East | North West | Yorkshire and Humberside | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 4435 | 2127 | 2280 | 673 | 776 | 793 | 861 | 1332 | 1948 | 1369 | 415 | 703 | 184 | 500 | 376 | 396 | 325 | 416 | 359 | 564 | 601 | 215 | 379 | 120 |
| Weighted base | 4435 | 2183 | 2224 | 661 | 817 | 757 | 814 | 1386 | 1182 | 1301 | 950 | 1002 | 176 | 485 | 366 | 389 | 323 | 410 | 373 | 603 | 605 | 209 | 374 | 124 |
| Very good | 789 18% | 400 18% | 383 17% | 133 20% GH | 193 24% GH | 153 20% GH | 123 15% | 187 13% | 261 22% JKL | 228 18% | 151 16% | 150 15% | 33 19% | 82 17% | 66 18% | 63 16% | 50 16% | 66 16% | 64 17% | 113 19% | 125 21% | 45 21% | 65 18% | 16 13% * |
| Good | 2033 46% | 1018 47% | 1005 45% | 258 39% | 361 44% | 382 51% DE | 399 49% D | 632 46% D | 567 48% L | 595 46% L | 492 52% JL | 379 38% | 75 43% | 217 45% | 155 42% | 173 44% | 141 43% | 203 50% | 185 50% | 269 45% | 273 45% | 105 50% | 182 49% | 55 44% * |
| Moderate | 1231 28% | 584 27% | 640 29% | 205 31% EF | 207 25% | 218 22% | 277 27% | 380 31% EF | 277 23% I | 380 29% I | 249 26% I | 326 32% IK | 45 25% | 145 30% V | 116 32% V | 120 31% V | 103 32% V | 104 25% | 100 27% | 165 27% | 153 25% | 45 22% | 97 26% | 40 32% * |
| Bad | 275 6% | 126 6% | 147 7% | 45 7% | 34 4% | 39 5% | 49 6% | 109 8% EF | 58 5% | 72 6% | 41 4% | 104 10% UK | 15 8% | 30 6% | 23 6% | 23 6% | 22 7% | 27 7% | 23 6% | 38 6% | 36 6% | 14 7% | 15 4% | 10 8% * |
| Very Bad | 70 2% | 39 2% | 32 1% | 9 1% | 18 2% | 11 1% | 14 2% | 19 1% | 11 1% | 17 1% | 12 1% | 31 3% UK | 6 3% SV | 9 2% S | 4 1% | 6 2% | 6 2% S | 7 2% S | * * | 10 2% | 9 2% | 1 * | 9 3% S | 2 2% * |
| Don't know | 15 * | 11 * | 4 * | 7 1% EGH | 1 * | 3 * | 1 * | 2 * | 4 * | 4 * | - - | 7 1% | 1 * | 2 * | 1 * | 1 * | - - | - - | 1 * | 3 1% | 4 1% | - - | 2 1% | - * |
| Prefer not to say | 21 * | 6 * | 13 1% | 3 1% | 4 * | 1 * | 8 1% F | 5 * | 4 * | 5 * | 6 1% | 5 1% | 1 1% | - - | 1 * | 3 1% | 2 1% | 2 1% | - - | 4 1% | 4 1% | - - | 3 1% | * * * |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|---------------|-------------|-------------|-------------|------------|------------------|-------------------|-----------------|----------------|------------------|-----------------|-----------------|------------------|----------------|------------|------------|------------|------------|------------|------------|------------|------------|---------------------|------------|----------------|
| NET: All GOOD | 2822 64% | 1419 65% | 1387 62% | 392 59% | 554 68% DH | 535 71% DGH | 523 64% H | 819 59% | 828 70% JL | 823 63% L | 642 68% L | 529 53% | 108 62% | 299 62% | 221 60% | 236 61% | 191 59% | 269 66% | 249 67% | 383 63% | 398 66% | 150 72% NOPQX | 248 66% | 71 58% * |
| NET: All BAD | 346 8% | 164 8% | 178 8% | 53 8% | 51 6% | 49 7% | 63 8% | 128 9% E | 69 6% | 89 7% | 53 6% | 135 13% UK | 21 12% S | 39 8% | 27 7% | 30 8% | 28 9% | 34 8% | 23 6% | 48 8% | 45 7% | 14 7% | 24 7% | 12 10% * |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions (5%): A,B/C,D/E/F/G,H,I,J/K/L,M/N/O/P/Q,R/S/T/U/V,W/X Minimum Base: 30(**) Small Base: 100(*)

ColumnMeans (5%): A,B/C,D/E/F/G,H,I,J/K/L,M/N/O/P/Q,R/S/T/U/V,W/X Minimum Base: 30(**) Small Base: 100(*)

21-087515-10 - 9th MArch 2022 - 14th March 2022
PUBLIC
BBC - Chronic Pain Survey
All UK adults aged 16-75

Q2. Throughout our lives, most of us have had pain from time to time (such as minor headaches, sprains, and toothaches). In the last 12 months, have you had pain other than these everyday kinds of pain?
All adults aged 16-75 in the UK

| | | Gender | | Age | | | | | Social Grade | | | | Region | | | | | | | | | | | |
|-------------------|-------------|------------------|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|------------------|------------|------------|--------------------------|----------------|------------------|-----------------|------------|-----------------|----------------|------------|--------------|------------------|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | AB | C1 | C2 | DE | North East | North West | Yorkshire and Humberside | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 4435 | 2127 | 2280 | 673 | 776 | 793 | 861 | 1332 | 1948 | 1369 | 415 | 703 | 184 | 500 | 376 | 396 | 325 | 416 | 359 | 564 | 601 | 215 | 379 | 120 |
| Weighted base | 4435 | 2183 | 2224 | 661 | 817 | 757 | 814 | 1386 | 1182 | 1301 | 950 | 1002 | 176 | 485 | 366 | 389 | 323 | 410 | 373 | 603 | 605 | 209 | 374 | 124 |
| Yes | 2167 49% | 1010 46% | 1143 51% B | 338 51% F | 383 47% | 340 45% | 388 48% | 718 52% F | 544 46% | 612 47% | 471 50% | 540 54% IJ | 91 51% | 238 49% | 183 50% | 187 48% | 176 54% ST | 205 50% | 171 46% | 266 44% | 294 49% | 109 52% | 181 48% | 67 54% * |
| No | 2095 47% | 1083 50% C | 999 45% | 268 41% | 384 47% D | 390 52% D | 401 49% D | 651 47% D | 592 50% L | 647 50% L | 453 48% L | 403 | 82 46% | 232 48% | 170 46% | 180 46% | 141 43% | 185 45% | 191 51% | 311 52% Q | 278 46% | 98 47% | 176 47% | 51 41% * |
| Don't know | 136 3% | 72 3% | 62 3% | 44 7% FGH | 43 5% GH | 26 3% H | 15 2% H | 8 1% | 37 3% | 32 2% | 18 2% | 49 5% IJK | 4 2% | 15 3% | 9 3% | 18 5% QV | 4 1% | 12 3% | 9 3% | 19 3% | 26 4% QV | 1 1% | 13 3% | 5 4% * |
| Prefer not to say | 37 1% | 17 1% | 19 1% | 10 2% F | 6 1% | 1 * | 10 1% F | 9 1% | 9 1% | 10 1% | 7 1% | 10 1% | - - | - - | 3 1% | 4 1% N | 2 1% | 8 2% N | 1 * | 7 1% N | 7 1% N | - - | 4 1% N | * * |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used
ColumnProportions (5%): A,B/C,D/E/F/G/H,I/J/K/L,M/N/O/P/Q/R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)
ColumnMeans (5%): A,B/C,D/E/F/G/H,I/J/K/L,M/N/O/P/Q/R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)

21-087515-10 - 9th MArch 2022 - 14th March 2022
PUBLIC
BBC - Chronic Pain Survey
All UK adults aged 16-75

Q3. In the last 12 months, have you personally experienced any chronic pain, that is pain that has lasted longer than three months?
All experienced Pain in the past 12 months

| | | Gender | | Age | | | | | Social Grade | | | | Region | | | | | | | | | | | |
|-------------------|-------------|------------|------------|------------------|-----------------|-----------------|-----------------|--------------------|-----------------|------------|------------------|-----------------|----------------|-----------------|--------------------------|---------------|---------------|-----------------|-----------------|-------------|-----------------|----------------------|-----------------|------------------|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | AB | C1 | C2 | DE | North East | North West | Yorkshire and Humberside | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 2122 | 977 | 1132 | 329 | 369 | 345 | 412 | 667 | 898 | 637 | 209 | 378 | 87 | 239 | 182 | 189 | 164 | 206 | 162 | 250 | 290 | 110 | 176 | 67 |
| Weighted base | 2167 | 1010 | 1143 | 338 | 383 | 340 | 388 | 718 | 544 | 612 | 471 | 540 | 91 | 238 | 183 | 187 | 176 | 205 | 171 | 266 | 294 | 109 | 181 | 67 |
| Yes | 1183 55% | 538 53% | 636 56% | 140 41% | 197 51% D | 169 50% | 201 52% D | 476 66% DEFG | 311 57% K | 337 55% | 226 48% | 309 57% K | 50 56% * | 139 58% V | 112 61% UVX | 105 56% | 87 49% | 118 58% V | 100 58% V | 143 54% | 147 50% | 47 43% * | 105 58% V | 29 43% * |
| No | 908 42% | 435 43% | 470 41% | 181 54% EH | 169 44% H | 158 47% H | 178 46% H | 221 31% | 216 40% | 262 43% | 228 48% IL | 202 37% | 37 41% * | 90 38% | 64 35% | 75 40% | 80 45% | 81 39% | 63 37% | 119 45% | 134 46% O | 59 54% NOPRSW* | 71 39% | 36 53% O* |
| Don't know | 64 3% | 31 3% | 33 3% | 16 5% H | 15 4% | 11 3% | 8 2% | 13 2% | 14 3% | 11 2% | 14 3% | 25 5% J | 1 1% * | 7 3% T | 6 3% T | 6 3% T | 9 5% T | 6 3% T | 9 5% T | - - - | 10 3% T | 3 2% T* | 5 3% T | 3 4% T* |
| Prefer not to say | 11 1% | 7 1% | 5 * | 1 * | 2 * | 1 * | 1 * | 7 1% | 2 * | 3 * | 3 1% | 3 1% | 2 2% * | 2 1% | 1 * | 1 * | - - - | - - - | - - - | 4 2% | 2 1% | - - * | - - - | - - * |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used
ColumnProportions (5%): A,B/C,D/E/F/G/H,I/J/K/L,M/N/O/P/Q/R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)
ColumnMeans (5%): A,B/C,D/E/F/G/H,I/J/K/L,M/N/O/P/Q/R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)

21-087515-10 - 9th MARCH 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q4. And how often do you currently experience chronic pain?

All experienced chronic pain in past 12 months

| | Gender | | | Age | | | | | Social Grade | | | | | Region | | | | | | | | | | |
|--|--------------|-------------|---------------|------------------|------------------|-----------------|-----------------|------------------|----------------|------------------|----------------|------------------|-------------------|-------------------|-----------------------------------|-------------------------|-------------------------|---------------------------|----------------------|-------------------|-----------------------|-------------------|-----------------|----------------------------|
| | Total (A) | Male (B) | Female (C) | 16-24 (D) | 25-34 (E) | 35-44 (F) | 45-54 (G) | 55-75 (H) | A8 (I) | C1 (J) | C2 (K) | DE (L) | North East (M) | North West (N) | Yorkshire and Humber (O) | West Midlands (P) | East Midlands (Q) | East of England (R) | South West (S) | South East (T) | Greater London (U) | Wales (V) | Scotland (W) | Northern Ireland (X) |
| Unweighted base | 1171 | 534 | 628 | 144 | 189 | 176 | 221 | 441 | 508 | 352 | 98 | 213 | 48 | 139 | 105 | 103 | 81 | 121 | 97 | 135 | 150 | 51 | 107 | 34 |
| Weighted base | 1183 | 538 | 636 | 140 | 197 | 169 | 201 | 476 | 311 | 337 | 226 | 309 | 50 | 139 | 112 | 105 | 87 | 118 | 100 | 143 | 147 | 47 | 105 | 29 |
| Every day | 377 32% | 157 29% | 216 34% | 22 16% | 41 21% | 56 33% DE | 68 34% DE | 190 40% DE | 88 28% | 95 28% | 57 25% * | 137 44% UK | 21 41% | 40 29% | 41 37% * | 32 30% * | 28 32% * | 44 37% * | 31 31% * | 51 36% | 39 27% | 11 24% * | 32 31% * | 7 25% ** |
| Most days | 339 29% | 159 29% | 179 28% | 21 15% | 55 28% D | 39 23% D | 64 32% D | 159 33% DF | 82 26% | 113 33% IL | 71 31% * | 74 24% | 18 35% * | 36 26% | 33 29% * | 37 35% * | 23 27% * | 37 31% * | 22 22% * | 33 23% | 43 29% | 15 32% * | 36 34% * | 7 22% ** |
| A few times a week | 183 15% | 81 15% | 102 16% | 28 20% | 29 15% | 33 20% | 32 16% | 61 13% | 60 19% L | 56 17% L | 35 16% * | 32 10% | 3 6% MRW | 29 21% MRW | 17 15% * | 18 17% * | 16 19% | 12 10% | 17 17% * | 18 12% | 30 20% MW | 12 24% MRW* | 9 8% + | 3 11% ** |
| A few times a month | 137 12% | 64 12% | 69 11% | 31 22% GH | 30 15% GH | 29 17% GH | 15 8% | 32 7% | 43 14% J | 26 8% | 29 13% * | 38 12% | 3 6% * | 20 14% | 13 11% * | 7 6% * | 9 10% * | 12 10% * | 14 14% * | 18 12% | 15 10% + | 4 9% + | 16 15% + | 6 19% ** |
| Once a month | 45 4% | 26 5% | 19 3% | 11 8% GH | 15 9% GH | 5 3% | 4 2% | 10 4% | 13 4% | 12 4% | 8 4% + | 11 3% | - 3% * | 4 3% | 3 5% * | 6 3% * | 2 3% | 2 2% * | 4 4% * | 7 5% | 11 8% R | 1 2% + | 3 3% + | 2 7% ** |
| Less often than once a month | 54 5% | 27 5% | 27 4% | 15 11% FGH | 21 11% FGH | 5 3% | 5 3% | 7 2% | 15 5% | 15 5% | 17 7% L* | 7 2% | - 2% * | 3 2% | 3 3% * | 3 3% | 7 8% | 7 6% * | 6 6% * | 7 5% | 6 4% + | 2 4% + | 7 7% + | 2 7% ** |
| I do not experience chronic pain anymore | 38 3% | 22 4% | 16 3% | 9 6% | 5 2% | 3 2% | 10 5% | 12 3% | 8 2% | 15 4% | 9 4% * | 6 2% | 5 9% PQ* | 5 4% | 2 1% * | 1 1% * | - 3% * | 4 3% * | 4 4% * | 6 4% | 4 3% | 2 5% + | 2 2% + | 3 9% ** |
| Don't know | 5 * | 2 * | 3 * | 2 2% | - 2% | - * | 1 1% | 2 * | 1 * | 1 * | - * | 3 1% | 1 3% * | 1 * | - 1% * | 1 * | * 1% * | 1 1% * | - 1% * | - 1% * | 2 1% | - 1% * | - 1% * | - 1% ** |
| Prefer not to answer | 5 * | 1 * | 4 1% | 2 1% | 1 1% | - * | 1 * | 2 * | 1 * | 2 1% | - 1% * | 3 1% | - 1% * | 2 1% | - 1% * | - 1% * | - 1% * | - 1% * | 1 1% * | 2 1% | - 1% * | - 1% * | - 1% * | - 1% ** |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------------------------------|-------------|------------|------------|------------|-----------------|------------------|------------------|-------------------|------------|-----------------|-----------------|-----------------|-------------------|-----------------|------------------|-----------------|-----------------|-----------------|----------------|------------|-----------------|----------------|------------------|-----------------|
| NET: At least most days | 716 61% | 316 59% | 395 62% | 43 31% | 96 49% D | 95 56% D | 133 66% DE | 349 73% DEF | 170 55% | 208 62% I | 128 56% * | 210 68% I | 38 76% NSU* | 76 55% | 68 66% * | 68 65% * | 51 59% * | 81 68% * | 53 53% * | 84 59% | 82 55% | 26 56% + | 68 65% + | 14 47% ** |
| NET: At least few times a week | 899 76% | 397 74% | 497 78% | 71 51% | 125 64% D | 128 75% DE | 165 82% DE | 410 86% DEF | 230 74% | 264 79% | 163 72% * | 242 78% * | 42 82% * | 106 76% * | 91 81% * | 86 82% * | 67 77% * | 93 79% * | 70 70% * | 102 71% | 111 76% | 38 80% + | 77 73% + | 17 59% ** |
| NET: At least a few times a month | 1036 88% | 461 86% | 566 89% | 101 73% | 155 79% | 156 92% DE | 180 90% DE | 443 93% DE | 273 88% | 291 86% | 192 85% * | 280 91% * | 45 88% * | 125 90% | 103 92% * | 93 89% * | 77 88% * | 105 89% * | 85 85% * | 120 84% | 126 86% | 42 89% + | 92 88% + | 23 78% ** |
| NET: At least monthly | 1081 91% | 486 90% | 586 92% | 112 80% | 170 86% | 162 96% DE | 184 92% D | 452 95% DE | 287 92% | 303 90% | 200 88% * | 291 94% * | 45 88% * | 129 93% | 106 95% * | 99 94% * | 79 91% * | 107 90% * | 88 89% * | 127 88% | 137 93% | 43 91% + | 95 91% + | 25 84% ** |
| NET: Any current chronic pain | 1135 96% | 513 95% | 613 96% | 127 91% | 192 97% D | 167 98% D | 190 94% | 460 97% D | 302 97% | 319 95% | 217 96% * | 298 96% * | 45 88% * | 132 95% | 110 98% M* | 102 97% * | 86 99% M* | 115 97% * | 94 95% * | 134 94% | 143 97% M | 45 95% + | 103 98% M* | 27 91% ** |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions (SN): A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X Minimum Base: 30(**) Small Base: 100(*)

ColumnMeans (SN): A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X Minimum Base: 30(**) Small Base: 100(*)

21-087515-10 - 9th March 2022 - 14th March 2022

PUBLIC
BBC - Chronic Pain Survey
All UK adults aged 16-75

Q4. And how often do you currently experience chronic pain? (rebased to include all respondents)

All adults aged 16-75 in the UK

| | Gender | | | Age | | | | | Social Grade | | | | | Region | | | | | | | | | | |
|--|--------------|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|--------------------|-----------------|-----------------|-----------------|------------------|-------------------|-------------------|------------------------------------|-------------------------|-------------------------|---------------------------|-------------------|-------------------|--------------------------|--------------|-----------------|----------------------------|
| | Total (A) | Male (B) | Female (C) | 16-24 (D) | 25-34 (E) | 35-44 (F) | 45-54 (G) | 55-75 (H) | A8 (I) | C1 (J) | C2 (K) | DE (L) | North East (M) | North West (N) | Yorkshire and Humbers (O) | West Midlands (P) | East Midlands (Q) | East of England (R) | South West (S) | South East (T) | Greater London (U) | Wales (V) | Scotland (W) | Northern Ireland (X) |
| Unweighted base | 4435 | 2127 | 2280 | 673 | 776 | 793 | 861 | 1332 | 1948 | 1369 | 415 | 703 | 184 | 500 | 376 | 396 | 325 | 416 | 359 | 564 | 601 | 215 | 379 | 120 |
| Weighted base | 4435 | 2183 | 2224 | 661 | 817 | 757 | 814 | 1386 | 1182 | 1301 | 950 | 1002 | 176 | 485 | 366 | 389 | 323 | 410 | 373 | 603 | 605 | 209 | 374 | 124 |
| Every day | 377 9% | 157 7% | 216 10% B | 22 3% | 41 5% | 56 7% D | 68 8% DE | 190 14% DEFG | 88 7% | 95 7% | 57 6% | 137 14% UK | 21 12% UV | 40 8% | 41 11% UV | 32 8% | 28 9% | 44 11% UV | 31 8% | 51 8% | 39 6% | 11 5% | 32 9% | 7 6% * |
| Most days | 339 8% | 159 7% | 179 8% | 21 3% | 55 7% D | 39 5% | 64 8% DF | 159 11% DEFG | 82 7% | 113 9% | 71 7% | 74 7% | 18 10% T | 36 9% | 33 9% | 37 7% | 23 9% | 37 6% | 22 5% | 33 7% | 43 7% | 15 7% | 36 10% T | 7 5% * |
| A few times a week | 183 4% | 81 4% | 102 5% | 28 4% | 29 4% | 33 4% | 32 4% | 61 4% L | 60 5% | 56 4% | 35 4% | 32 3% | 3 2% | 29 6% MTW | 17 5% | 18 5% | 16 5% | 12 3% | 17 5% | 18 3% | 30 5% | 12 6% | 9 2% | 3 3% * |
| A few times a month | 137 3% | 64 3% | 69 3% GH | 31 5% | 30 4% | 29 4% G | 15 4% | 32 4% J | 43 2% | 26 3% | 29 3% | 38 4% J | 3 2% | 20 4% | 13 2% | 7 3% | 9 3% | 12 4% | 14 3% | 18 2% | 15 2% | 4 2% | 16 4% | 6 5% * |
| Once a month | 45 1% | 26 1% | 19 1% G | 11 2% GH | 15 2% GH | 5 1% | 4 * | 10 1% | 13 1% | 12 1% | 8 1% | 11 1% | - - | 4 1% | 3 1% | 6 1% | 2 1% | 2 * | 4 1% * | 7 1% | 11 2% | 1 * | 3 1% | 2 2% * |
| Less often than once a month | 54 1% | 27 1% | 27 1% FGH | 15 2% FGH | 21 3% FGH | 5 1% | 5 1% | 7 1% | 15 2% | 15 1% | 17 2% | 7 1% | - - | 3 1% | 3 1% | 3 1% | 7 2% | 7 2% | 6 1% | 7 1% | 6 1% | 2 1% | 7 2% | 2 2% * |
| I do not experience chronic pain anymore | 38 1% | 22 1% | 16 1% | 9 1% | 5 1% | 3 * | 10 1% | 12 1% | 8 1% | 15 1% | 9 1% | 6 1% | 5 3% PQ | 5 1% | 2 * | 1 * | - - | 4 1% * | 4 1% | 6 1% | 4 1% | 2 1% | 2 1% | 3 2% Q* |
| Don't know | 5 * | 2 * | 3 * | 2 * | - - | - - | 1 * | 2 * | 1 * | 1 * | - - | 3 * | 1 1% | - - | 1 * | 1 * | 1 * | - - | - - | 2 * | - - | - - | - - | - * |
| Prefer not to answer | 5 * | 1 * | 4 * | 2 * | 1 * | - - | 1 * | 2 * | 1 * | 2 * | - - | 3 * | - - | 2 * | - * | 1 * | - - | - - | 1 * | 2 * | - * | - - | - - | - * |
| No answer | 3252 73% | 1645 75% C | 1587 71% | 521 79% H | 620 76% H | 587 78% H | 613 75% H | 910 66% | 871 74% L | 964 74% L | 724 76% L | 693 69% | 125 71% | 346 71% | 254 69% | 284 73% | 236 73% | 291 71% | 273 73% | 460 76% O | 457 76% | 161 77% | 269 72% | 95 76% * |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------------------------------|-------------|------------------|-----------------|-----------------|-----------------|-----------------|--------------------|--------------------|-----------------|-----------------|-----------------|------------------|--------------------|-----------------|------------------|------------|------------|-----------------|------------|-----------------|------------|------------|------------|----------------|
| NET: At least most days | 716 16% | 316 14% | 395 18% B | 43 7% | 96 12% D | 95 13% | 133 16% DE | 349 25% DEFG | 170 14% | 208 16% | 128 13% | 210 21% UK | 38 22% STUVK | 76 16% | 74 20% TUV | 68 18% | 51 16% | 81 20% TU | 53 14% | 84 14% | 82 14% | 26 13% | 68 18% | 14 11% * |
| NET: At least few times a week | 899 20% | 397 18% | 497 22% B | 71 11% | 125 15% D | 128 17% D | 165 20% DE | 410 30% DEFG | 230 19% | 264 20% | 163 17% | 242 24% IK | 42 24% | 106 22% | 91 25% TUX | 86 22% | 67 21% | 93 23% T | 70 19% | 102 17% | 111 18% | 38 18% | 77 20% | 17 14% * |
| NET: At least a few times a month | 1036 23% | 461 21% | 566 25% B | 101 15% | 155 19% D | 156 21% D | 180 22% DEFG | 443 32% DEFG | 273 23% | 291 22% | 192 20% | 280 28% UK | 45 25% | 125 26% T | 103 28% TU | 93 24% | 77 24% | 105 26% T | 85 23% | 120 20% | 126 21% | 42 20% | 92 25% | 23 18% * |
| NET: At least monthly | 1081 24% | 486 22% | 586 26% B | 112 17% | 170 21% D | 162 21% D | 184 23% DEFG | 452 33% DEFG | 287 24% | 303 23% | 200 21% | 291 29% UK | 45 25% | 129 27% | 106 29% T | 99 25% | 79 24% | 107 26% T | 88 24% | 127 21% | 137 23% | 43 21% | 95 26% | 25 20% * |
| NET: Any current chronic pain | 1135 26% | 513 24% | 613 28% B | 127 19% | 192 23% D | 167 22% D | 190 23% DEFG | 460 33% DEFG | 302 26% | 319 24% | 217 23% | 298 30% UK | 45 25% | 132 27% | 110 30% T | 102 26% | 86 27% | 115 28% | 94 25% | 134 22% | 143 24% | 45 22% | 103 27% | 27 21% * |
| NET: No chronic pain | 3290 74% | 1667 76% C | 1603 72% | 530 80% H | 624 76% H | 590 78% H | 623 77% H | 923 67% | 878 74% L | 980 75% L | 733 77% L | 698 70% | 130 74% | 352 72% | 255 70% O | 285 73% | 236 73% | 295 72% | 277 74% | 465 76% O | 462 76% | 164 77% | 271 73% | 97 79% * |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulas used

ColumnProportions (5%): A,B/C,D,E/F,G/H,I/J,K/L,M/N/O/P/Q,R/S,T,U/V/W/X Minimum Base: 30 (**) Small Base: 100 (*)

ColumnMeans (5%): A,B/C,D,E/F,G/H,I/J,K/L,M/N/O/P/Q,R/S,T,U/V,W/X Minimum Base: 30 (**) Small Base: 100 (*)

21-087515-10 - 9th MArch 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q5. Thinking about this chronic pain, which one of the following statements most closely reflects your experience?

All who currently experience chronic pain

| | | Gender | | | Age | | | | Social Grade | | | | Region | | | | | | | | | | | |
|---|-------------|------------|------------|-------------------|------------------|----------------|------------------|-------------------|---------------|-----------------|-----------------|------------------|------------------|------------|--------------------------|----------------|------------------|-----------------|------------------|-----------------|-----------------|----------------|----------------|------------------|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | AB | C1 | C2 | DE | North East | North West | Yorkshire and Humberside | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 1125 | 509 | 607 | 133 | 183 | 173 | 210 | 426 | 492 | 334 | 94 | 205 | 44 | 133 | 102 | 99 | 80 | 116 | 93 | 126 | 146 | 49 | 105 | 32 |
| Weighted base | 1135 | 513 | 613 | 127 | 192 | 167 | 190 | 460 | 302 | 319 | 217 | 298 | 45 | 132 | 110 | 102 | 86 | 115 | 94 | 134 | 143 | 45 | 103 | 27 |
| It impacts my ability to do more than one "major activity" such as being able to work, go to school/ college, do housework, leave the house, socialise most of the time, etc. | 306 27% | 127 25% | 175 29% | 32 25% | 50 26% | 60 36% H | 54 29% | 111 24% | 81 27% | 68 21% | 48 22% * | 109 37% UK | 16 35% * | 39 29% | 39 36% SU* | 22 22% * | 20 23% * | 37 32% * | 18 19% * | 32 24% * | 32 22% | 14 30% * | 31 30% * | 7 28% ** |
| It impacts my ability to do one "major activity" such as being able to work, go to school/ college, do housework, leave the house, socialise most of the time, etc. | 207 18% | 96 19% | 108 18% | 53 42% EFGH | 52 27% FGH | 28 17% H | 26 14% | 47 10% | 54 18% | 55 17% | 43 20% * | 54 18% | 9 20% * | 22 17% | 18 17% * | 11 11% * | 10 11% * | 18 16% * | 24 25% PQ* | 27 20% * | 36 25% PQ | 9 19% * | 17 17% * | 7 26% ** |
| It impacts my life, but I am able to do most daily activities most of the time | 550 48% | 251 49% | 298 49% | 34 27% | 77 40% D | 69 41% D | 100 53% DE | 270 59% DEF | 140 46% | 170 53% L | 115 53% * | 125 42% | 19 42% * | 61 47% | 49 45% * | 58 57% * | 53 62% DU* | 55 48% * | 44 47% * | 64 48% * | 64 45% | 21 46% * | 50 49% * | 11 40% ** |
| It does not impact my daily life | 66 6% | 37 7% | 28 5% | 8 6% | 12 6% | 8 5% | 9 5% | 29 6% | 26 8% L | 24 8% L | 10 5% * | 6 2% | 1 3% * | 8 6% | 3 3% * | 10 10% * | 4 4% * | 3 3% * | 8 9% * | 10 8% * | 11 7% | 2 4% * | 4 4% * | 1 3% ** |
| Don't know | 2 * | 2 * | - - | - - | 1 * | - - | - - | 1 * | 1 * | 1 * | - * | - - | - - | - - | - - | - * | - * | - * | - * | - * | 1 1% * | - * | - * | 1 3% ** |
| Prefer not to answer | 4 * | - - | 4 1% | - - | - - | 1 1% | 1 * | 2 * | - - | 1 * | - * | 3 1% | - * | 1 1% | - * | 1 1% | - * | 2 2% * | - * | - * | - - | - * | - * | - ** |
| NET: All impacted - at least 1 activity | 513 45% | 223 44% | 283 46% | 85 67% EFGH | 102 53% H | 88 53% H | 80 42% | 158 34% | 136 45% | 123 39% | 91 42% * | 164 55% UK | 25 55% PQ* | 61 46% | 57 52% PQ* | 33 33% * | 29 34% * | 55 48% * | 42 44% * | 59 44% * | 67 47% | 22 50% * | 48 47% * | 14 54% ** |
| NET: All impacted in any way | 1063 94% | 474 92% | 581 95% | 120 94% | 179 93% | 157 94% | 180 95% | 428 93% | 275 91% | 293 92% | 206 95% * | 289 97% IJ | 44 97% * | 122 93% | 106 97% * | 91 89% * | 82 96% * | 109 96% * | 86 91% * | 124 92% * | 132 92% | 43 96% * | 99 96% * | 25 94% ** |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions (5%): A,B/C,D/E/F/G,H,I/J/K/L,M,N/O,P/Q,R/S/T/U/V,W/X Minimum Base: 30(**) Small Base: 100(*)

ColumnMeans (5%): A,B/C,D/E/F/G,H,I/J/K/L,M,N/O,P/Q,R/S/T/U/V,W/X Minimum Base: 30(**) Small Base: 100(*)

21-087515-10 - 9th March 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q5B. Which, if any, of the following types of activity would you say are impacted by your chronic pain? If there are no specific activities which you feel are impacted by this chronic pain, please choose the "None" option

All with activity-limiting chronic pain

| | | Gender | | | Age | | | | Social Grade | | | | Region | | | | | | | | | | | |
|--|--------------|-------------|---------------|--------------|--------------|--------------|--------------|--------------|--------------|------------|-----------|-------------|-------------------|-------------------|---------------------------------|-------------------------|-------------------------|---------------------------|-------------------|-------------------|--------------------------|--------------|-----------------|----------------------------|
| | Total (A) | Male (B) | Female (C) | 16-24 (D) | 25-34 (E) | 35-44 (F) | 45-54 (G) | 55-75 (H) | A8 (I) | C1 (J) | C2 (K) | DE (L) | North East (M) | North West (N) | Yorkshire and Humbers (O) | West Midlands (P) | East Midlands (Q) | East of England (R) | South West (S) | South East (T) | Greater London (U) | Wales (V) | Scotland (W) | Northern Ireland (X) |
| Unweighted base | 505 | 227 | 271 | 85 | 101 | 87 | 84 | 148 | 220 | 130 | 42 | 113 | 24 | 56 | 53 | 34 | 28 | 54 | 40 | 54 | 76 | 23 | 49 | 14 |
| Weighted base | 513 | 223 | 283 | 85 | 102 | 88 | 80 | 158 | 136 | 123 | 91 | 164 | 25 | 61 | 57 | 33 | 29 | 55 | 42 | 59 | 67 | 22 | 48 | 14 |
| Exercising | 321 63% | 129 58% | 186 66% | 41 49% | 49 48% | 52 59% | 60 74% | 118 75% | 90 66% | 85 69% | 44 48% | 102 62% | 15 61% | 31 52% | 37 65% | 21 64% | 16 55% | 41 75% | 29 70% | 34 58% | 39 59% | 14 61% | 33 69% | 9 63% |
| Domestic chores (i.e. looking after my home) | 310 60% | 113 51% | 191 68% | 25 29% | 44 43% | 56 63% | 58 73% | 127 80% | 73 54% | 83 67% | 48 53% | 106 65% | 12 48% | 42 69% | 36 62% | 20 62% | 16 54% | 35 63% | 23 55% | 40 67% | 30 45% | 11 50% | 37 77% | 8 57% |
| Going shopping | 255 50% | 91 41% | 160 57% | 18 21% | 42 41% | 47 D* | 49 DE* | 100 63% | 66 49% | 58 47% | 29 32% | 101 62% | 11 47% | 33 55% | 34 59% | 16 48% | 18 60% | 34 63% | 23 55% | 24 40% | 23 35% | 5 23% | 29 60% | 4 28% |
| Socialising | 252 49% | 98 44% | 151 53% | 32 37% | 47 * | 44 50% | 52 65% | 77 49% | 69 51% | 50 41% | 37 41% | 96 59% | 12 50% | 25 41% | 35 60% | 15 46% | 20 70% | 27 50% | 20 47% | 24 41% | 11 45% | 25 51% | 6 52% | 42% |
| Leaving the house/ home | 251 49% | 94 42% | 153 54% | 29 34% | 47 47% | 44 51% | 47 59% | 84 53% | 62 46% | 51 41% | 46 50% | 93 57% | 14 58% | 20 33% | 34 59% | 17 52% | 16 55% | 31 56% | 21 51% | 27 46% | 28 41% | 7 31% | 28 57% | 8 56% |
| Work or study | 211 41% | 86 39% | 121 43% | 25 29% | 36 35% | 41 47% | 46 58% | 63 40% | 54 40% | 52 43% | 27 30% | 78 47% | 13 53% | 18 29% | 21 36% | 12 37% | 12 42% | 24 44% | 15 37% | 30 47% | 31 28% | 6 28% | 22 46% | 6 44% |
| Being intimate with a partner | 170 33% | 74 33% | 93 33% | 23 27% | 33 33% | 29 33% | 32 40% | 52 33% | 46 34% | 38 31% | 24 26% | 63 38% | 4 17% | 19 30% | 22 38% | 14 43% | 10 35% | 16 29% | 15 37% | 24 41% | 21 31% | 5 21% | 18 36% | 2 15% |
| Caring for children or other family members | 115 22% | 39 18% | 73 26% | 15 17% | 24 24% | 29 33% | 17 21% | 30 19% | 35 26% | 24 20% | 16 18% | 40 24% | 5 22% | 18 29% | 19 33% | 5 14% | 4 13% | 16 30% | 8 19% | 10 16% | 15 22% | 6 27% | 6 13% | 3 24% |
| Other (please specify) | 13 3% | 4 2% | 9 3% | - * | - * | 1 1% | 5 6% | 8 5% | 2 2% | 6 5% | - * | 5 3% | - * | 1 2% | 1 2% | - * | - * | 2 4% | 2 5% | 2 3% | 1 1% | 1 1% | 1 3% | 2 14% |
| NET: 1 or more activities | 507 99% | 221 99% | 280 99% | 85 99% | 101 99% | 88 100% | 80 100% | 153 97% | 135 99% | 120 98% | 89 98% | 164 100% | 24 97% | 61 100% | 57 100% | 32 97% | 29 100% | 52 96% | 40 95% | 59 100% | 67 100% | 22 100% | 48 100% | 14 100% |
| None | 2 * | 2 1% | - * | - * | 1 1% | - * | - * | 1 1% | 1 1% | 1 1% | - * | - * | 1 3% | - * | - * | - * | - * | - * | 1 3% | - * | - * | - * | - * | - * |
| Don't know | 1 * | 1 * | - * | 1 1% | - * | - * | - * | - * | - 1% | 1 1% | - * | - * | - * | - * | - * | - * | - * | - * | 1 2% | - * | - * | - * | - * | - * |
| Prefer not to answer | 3 1% | - 1% | 3 1% | - * | - * | - * | - * | 3 2% | - 1% | 1 1% | 2 2% | - * | - * | - * | - * | 1 3% | - * | 2 4% | - * | - * | - * | - * | - * | - * |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions (5N): A,B/C,D/E/F/G/H,I/J/K/L,M/N/O/P/Q/R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(**)

ColumnMeans (5N): A,B/C,D/E/F/G/H,I/J/K/L,M/N/O/P/Q,R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(**)

21-087515-10 - 9th MArch 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q6. On balance, which, if any, of the following statements BEST describes the extent to which you are able to cope with this chronic pain, day-to-day?

All who currently experience chronic pain

| | | Gender | | | Age | | | | | Social Grade | | | | Region | | | | | | | | | | |
|---|-----------------|-----------------|-----------------|----------------|----------------|----------------|------------|-------------------|-----------------|-----------------|------------------|------------------|------------------|------------------|---------------------------|-----------------|------------------|-----------------|----------------|------------------|-------------------|----------------|------------------|------------------|
| | Total | Male | Female | | | | | | | | | | | | Yorkshire and Humbersid e | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 1125 | 509 | 607 | 133 | 183 | 173 | 210 | 426 | 492 | 334 | 94 | 205 | 44 | 133 | 102 | 99 | 80 | 116 | 93 | 126 | 146 | 49 | 105 | 32 |
| Weighted base | 1135 | 513 | 613 | 127 | 192 | 167 | 190 | 460 | 302 | 319 | 217 | 298 | 45 | 132 | 110 | 102 | 86 | 115 | 94 | 134 | 143 | 45 | 103 | 27 |
| I can cope with my pain all/almost all the time | 216 19% | 116 23% C | 98 16% | 15 12% | 42 22% | 30 18% | 37 19% | 92 20% | 71 24% L | 64 20% | 41 19% * | 40 14% | 6 13% * | 28 21% | 16 15% * | 23 23% * | 11 13% * | 24 21% * | 22 23% * | 22 16% * | 36 25% | 8 18% * | 17 17% * | 3 9% ** |
| I can cope with my pain more often than not | 451 40% | 212 41% | 236 38% | 45 35% | 54 28% | 65 39% | 74 39% | 214 47% DE | 128 42% L | 131 41% L | 102 47% L* | 90 30% | 16 35% * | 63 47% PU | 42 38% * | 33 32% * | 44 51% PU* | 45 39% * | 36 38% * | 53 40% * | 49 34% | 23 50% * | 37 37% * | 11 43% ** |
| I can only cope with my pain about half of the time, | 289 26% | 108 21% | 180 29% B | 44 34% H | 52 27% | 40 24% | 52 27% | 102 22% | 58 19% | 83 26% I | 47 22% * | 101 34% IK | 10 23% * | 25 19% | 28 25% * | 26 26% * | 20 23% * | 30 26% * | 25 27% * | 44 33% NU* | 27 19% | 12 27% * | 36 36% NU* | 6 22% ** |
| I cannot cope with my pain more often than not | 112 10% | 43 8% | 69 11% | 15 12% | 25 13% | 21 12% | 18 10% | 33 7% | 27 9% | 31 10% | 21 10% * | 34 11% | 7 16% Q* | 10 8% | 16 14% Q* | 14 14% * | 4 4% * | 9 8% * | 7 8% * | 11 8% * | 20 14% | 1 3% * | 8 8% * | 5 20% ** |
| I cannot cope with my pain all/almost all of the time | 52 5% | 27 5% | 24 4% | 6 5% | 16 8% H | 9 5% | 7 4% | 14 3% | 17 6% J | 7 2% | 6 3% * | 22 7% J | 3 7% * | 3 2% | 5 4% * | 5 5% * | 6 7% W* | 8 7% W* | 4 4% * | 4 3% * | 11 8% W | 1 1% * | 1 1% * | 2 6% ** |
| Don't know | 7 1% | 6 1% | 1 * | 1 1% | 2 1% | - | 1 1% | 3 1% | - | - | - | 7 2% IJ | 1 3% * | 1 1% | 3 3% * | - | - | - | - | - | - | - | 1 1% * | - |
| Prefer not to answer | 7 1% | 2 * | 5 1% | 1 1% | 1 1% | 3 2% | 1 1% | 1 * | - | 3 1% | - | 4 1% I | 1 3% * | 3 2% | - | 1 1% * | 1 1% * | - | - | - | - | - | 1 1% * | - |
| NET: Can cope more than half of the time | 667 59% C | 328 64% | 334 54% | 60 47% | 96 50% | 95 57% | 111 58% | 306 67% DEF | 199 66% L | 195 61% L | 143 66% L* | 130 44% | 21 48% * | 90 68% MOW | 58 53% * | 56 55% * | 55 64% * | 68 60% * | 58 61% * | 75 56% * | 85 59% | 31 68% * | 55 54% * | 14 52% ** |
| NET: Cannot cope more than half of the time | 164 14% | 69 14% | 93 15% | 22 17% | 40 21% H | 29 17% H | 25 13% | 48 10% | 44 15% | 38 12% | 27 12% * | 56 19% J | 10 23% VW* | 13 10% | 21 19% V* | 19 19% V* | 10 11% * | 16 14% * | 11 12% * | 15 11% * | 31 21% NTVW | 2 4% * | 9 9% * | 7 26% ** |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions (5%): A,B/C,D/E/F/G,H,I,J/K/L,M,N/O,P/Q,R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)

ColumnMeans (5%): A,B/C,D/E/F/G,H,I,J/K/L,M,N/O,P/Q,R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)

21-087515-10 - 9th MArch 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q7. Have you had any direct contact with a healthcare professional for this chronic pain in the last 12 months?

All who currently experience chronic pain

| | | Gender | | | Age | | | | | Social Grade | | | | Region | | | | | | | | | | | |
|--|------------|------------|------------|-----------------|-------------------|-----------------|-----------------|-------------------|-----------------|-----------------|-----------------|--------------|------------------|----------------|---------------------------|-----------------|----------------|-----------------|------------------|-------------------|------------------------|------------------|-----------------|------------------|--|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | AB | C1 | C2 | DE | North East | North West | Yorkshire and Humbersid e | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland | |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) | |
| Unweighted base | 1125 | 509 | 607 | 133 | 183 | 173 | 210 | 426 | 492 | 334 | 94 | 205 | 44 | 133 | 102 | 99 | 80 | 116 | 93 | 126 | 146 | 49 | 105 | 32 | |
| Weighted base | 1135 | 513 | 613 | 127 | 192 | 167 | 190 | 460 | 302 | 319 | 217 | 298 | 45 | 132 | 110 | 102 | 86 | 115 | 94 | 134 | 143 | 45 | 103 | 27 | |
| Yes – in-person | 467 41% | 203 40% | 261 43% | 61 48% | 73 38% | 69 41% | 78 41% | 186 40% | 135 45% | 125 39% | 81 37% * | 126 42% | 20 45% * | 63 48% | 47 43% * | 36 35% * | 29 34% * | 51 44% * | 38 40% * | 49 37% * | 60 42% | 17 38% * | 48 47% * | 10 37% ** | |
| Yes – via the telephone | 367 32% | 159 31% | 206 34% | 40 31% | 73 38% | 59 35% | 57 30% | 139 30% | 103 34% | 93 29% | 70 32% * | 101 34% | 13 29% * | 38 29% | 36 33% * | 35 34% * | 33 38% * | 36 31% * | 30 32% * | 34 26% * | 53 37% | 15 34% * | 35 34% * | 8 32% ** | |
| Yes – virtually (e.g. Zoom or Teams calls, etc) | 132 12% | 66 13% | 65 11% | 29 23% GH | 41 21% GH | 26 16% GH | 13 7% | 22 5% | 51 17% JL | 29 9% | 22 10% * | 31 10% | 3 6% * | 19 14% | 12 11% * | 7 7% * | 5 6% * | 13 11% * | 11 11% * | 15 11% * | 33 23% MOPQRSTVW | 3 6% * | 12 11% * | 1 2% ** | |
| No direct contact with a healthcare professional for this chronic pain in the last 12 months | 354 31% | 168 33% | 182 30% | 23 18% | 33 17% | 47 28% E | 68 36% DE | 182 40% DEF | 85 28% | 115 36% I | 68 32% * | 86 29% | 13 29% * | 31 24% | 36 33% U* | 33 32% U* | 28 32% * | 30 26% * | 37 40% NU* | 56 42% NRU* | 28 19% | 18 41% NU* | 33 32% U* | 10 39% ** | |
| Don't know | 12 1% | 6 1% | 6 1% | 5 4% GH | 3 2% | 3 2% | - - * | 1 * | 1 * | 3 1% | 4 2% * | 4 1% | - - * | 4 3% | 1 1% * | 1 1% * | 2 2% * | - - * | - - * | 3 2% * | 1 1% | - - * | 1 1% * | - - ** | |
| Prefer not to say | 12 1% | 5 1% | 7 1% | 1 1% | 3 2% | 5 3% H | 2 1% | 1 * | - - | 4 1% I | 3 1% * | 6 2% I | 3 6% OQRT* | 2 1% | - - * | 4 4% * | - - * | - - * | 1 1% * | - - * | 1 1% | - - * | 2 2% * | - - ** | |
| NET: Any direct contact | 756 67% | 334 65% | 418 68% | 98 77% GH | 152 79% FGH | 113 68% | 119 63% | 275 60% | 216 71% J | 196 62% | 142 65% * | 203 68% | 29 65% * | 95 72% T | 73 66% * | 65 63% * | 57 66% * | 85 74% T* | 56 59% * | 75 56% * | 113 79% PSTVW | 27 59% * | 66 65% * | 16 61% ** | |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions (5%): A,B/C,D,E/F,G/H,I/J/K/L,M/N/O/P/Q,R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)

ColumnMeans (5%): A,B/C,D,E/F,G/H,I/J/K/L,M/N/O/P/Q,R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)

21-087515-10 - 9th March 2022 - 14th March 2022
PUBLIC
BBC - Chronic Pain Survey
All UK adults aged 16-75

Q8. Has a healthcare professional given you a formal diagnosis of the cause of this chronic pain?
All who currently experience chronic pain

| | | Gender | | Age | | | | | Social Grade | | | | Region | | | | | | | | | | | |
|-------------------|------------|------------|------------|--------------|------------|----------------|----------------|------------------|--------------|--------------|-----------------|--------------|-------------------|------------|---------------------------|------------------|----------------|-----------------|----------------|----------------|----------------|----------------|----------------|------------------|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | AB | C1 | C2 | DE | North East | North West | Yorkshire and Humbersid e | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 1125 | 509 | 607 | 133 | 183 | 173 | 210 | 426 | 492 | 334 | 94 | 205 | 44 | 133 | 102 | 99 | 80 | 116 | 93 | 126 | 146 | 49 | 105 | 32 |
| Weighted base | 1135 | 513 | 613 | 127 | 192 | 167 | 190 | 460 | 302 | 319 | 217 | 298 | 45 | 132 | 110 | 102 | 86 | 115 | 94 | 134 | 143 | 45 | 103 | 27 |
| Yes | 766 67% | 332 65% | 428 70% | 86 68% | 127 66% | 101 61% | 116 61% | 336 73% FG | 213 71% | 208 65% | 152 70% * | 193 65% | 27 61% * | 91 69% | 79 72% * | 64 63% * | 53 62% * | 77 67% * | 60 64% * | 94 70% * | 100 70% | 31 70% * | 67 65% * | 22 82% ** |
| No | 341 30% | 167 33% | 171 28% | 35 28% | 57 29% | 63 38% H | 69 36% H | 118 26% | 82 27% | 102 32% | 62 29% * | 95 32% | 13 29% * | 38 29% | 30 27% * | 32 31% * | 31 36% * | 37 32% * | 30 31% * | 37 27% * | 42 29% | 14 30% * | 34 33% * | 5 18% ** |
| Don't know | 16 1% | 10 2% | 6 1% | 4 3% F | 5 3% | - - | 4 2% | 3 1% | 7 2% | 5 2% | - - * | 4 1% | 2 4% * | 1 1% | * * * | 2 1% * | 1 1% * | 1 1% * | 3 3% * | 4 3% * | 1 1% | - - * | 1 1% * | - - ** |
| Prefer not to say | 12 1% | 4 1% | 8 1% | 2 2% | 4 2% | 3 2% | 1 1% | 2 * | - - | 4 1% I | 3 1% * | 6 2% I | 3 6% ORTUW* | 2 1% | - - * | 5 5% ORTU* | 1 1% * | - - * | 2 2% * | - - * | - - * | - - * | - - * | - - ** |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used
ColumnProportions (5%): A,B/C,D/E/F/G/H,I/J/K/L,M/N/O/P/Q/R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)
ColumnMeans (5%): A,B/C,D/E/F/G/H,I/J/K/L,M/N/O/P/Q/R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)

21-087515-10 - 9th March 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q9. And which of the following diagnoses did you receive from a healthcare professional in relation to this chronic pain, or was it something else?

All with diagnosis of their chronic pain

| | Gender | | | Age | | | | | Social Grade | | | | | | | | | | Region | | | | | | | | | |
|---|--------------|-------------|---------------|--------------|--------------|--------------|--------------|--------------|--------------|-----------|-----------|-----------|-------------------|-------------------|--------------------------------|-------------------------|-------------------------|---------------------------|----------------------|-------------------|--------------------------|--------------|-----------------|----------------------------|--|--|--|--|
| | Total (A) | Male (B) | Female (C) | 16-24 (D) | 25-34 (E) | 35-44 (F) | 45-54 (G) | 55-75 (H) | A8 (I) | C1 (J) | C2 (K) | DE (L) | North East (M) | North West (N) | Yorkshire and Humber (O) | West Midlands (P) | East Midlands (Q) | East of England (R) | South West (S) | South East (T) | Greater London (U) | Wales (V) | Scotland (W) | Northern Ireland (X) | | | | |
| Unweighted base | 760 | 338 | 416 | 88 | 120 | 110 | 134 | 308 | 345 | 218 | 66 | 131 | 27 | 91 | 73 | 65 | 48 | 78 | 58 | 88 | 104 | 33 | 70 | 25 | | | | |
| Weighted base | 766 | 332 | 428 | 86 | 127 | 101 | 116 | 336 | 213 | 208 | 152 | 193 | 27 | 91 | 79 | 64 | 53 | 77 | 60 | 94 | 100 | 31 | 67 | 22 | | | | |
| Arthritis (i.e. osteoarthritis, rheumatoid arthritis, psoriatic arthritis etc.) | 285 37% | 118 36% | 167 39% | 17 20% | 13 10% | 25 25% | 34 30% | 196 58% | 69 32% | 81 39% | 51 34% | 85 44% | 16 59% | 37 40% | 37 46% | 21 33% | 21 39% | 23 29% | 21 35% | 31 33% | 34 34% | 9 30% | 24 36% | 12 54% | | | | |
| Other Back pain (e.g. degenerative disc disease etc.) | 136 18% | 60 18% | 75 18% | 8 9% | 18 15% | 16 15% | 20 17% | 75 22% | 26 12% | 38 18% | 31 20% | 42 22% | 11 40% | 14 15% | 17 21% | 18 28% | 13 25% | 7 9% | 12 13% | 13 14% | 8 8% | 4 13% | 16 24% | 4 19% | | | | |
| Nerve damage ('neuropathic pain') | 96 13% | 43 13% | 52 12% | 9 10% | 15 12% | 17 17% | 17 15% | 38 11% | 27 13% | 23 11% | 12 8% | 34 18% | 5 19% | 7 7% | 11 14% | 10 16% | 6 12% | 13 17% | 4 7% | 8 8% | 19 19% | 3 9% | 6 9% | 4 20% | | | | |
| Fibromyalgia | 88 11% | 33 10% | 55 13% | 7 8% | 24 19% | 10 9% | 13 11% | 35 10% | 24 11% | 26 13% | 10 6% | 28 14% | 3 12% | 11 12% | 9 12% | 9 14% | 8 14% | 10 13% | 6 11% | 7 7% | 11 11% | 4 13% | 4 6% | 5 24% | | | | |
| Migraine | 84 11% | 38 11% | 44 10% | 12 14% | 28 22% | 18 18% | 9 5% | 17 18% | 39 9% | 19 9% | 13 9% | 13 7% | 1 3% | 8 9% | 10 13% | 6 10% | 5 10% | 8 10% | 6 9% | 8 8% | 18 18% | 5 15% | 8 12% | 2 8% | | | | |
| Any bowel condition (e.g. ulcerative colitis, Chron's disease, IBD, proctitis etc.) | 72 9% | 39 12% | 33 8% | 18 21% | 18 14% | 8 8% | 5 4% | 23 7% | 23 11% | 16 8% | 15 10% | 18 9% | 5 19% | 3 3% | 3 3% | 12 18% | 4 7% | 5 6% | 6 10% | 11 12% | 13 13% | 4 13% | 4 6% | 3 15% | | | | |
| Chronic fatigue syndrome/myalgic encephalomyelitis (ME) | 63 8% | 31 9% | 29 7% | 13 15% | 20 16% | 11 11% | 5 4% | 14 4% | 24 11% | 14 7% | 12 8% | 13 7% | - * | 7 7% | 6 8% | 3 5% | 3 5% | 10 13% | 1 2% | 12 10% | 10 15% | 5 6% | 4 9% | 2 9% | | | | |
| Pelvic pain, other than bowel conditions (e.g. Endometriosis, pelvic inflammatory disease etc.) | 62 8% | 31 9% | 31 7% | 12 14% | 21 17% | 17 17% | 10 9% | 2 1% | 25 12% | 14 7% | 9 6% | 14 7% | 4 13% | 6 6% | 6 7% | 3 4% | 2 5% | 5 7% | 3 5% | 4 4% | 22 22% | 4 13% | 4 6% | - * | | | | |
| Long Covid | 45 6% | 30 9% | 16 4% | 14 16% | 23 18% | 4 4% | 2 2% | 2 1% | 18 9% | 5 3% | 16 11% | 5 3% | - 12% | 11 w* | 4 * | 3 * | 1 * | 5 * | 3 * | 6 * | 9 * | - ** | 1 * | 1 ** | | | | |
| Osteoporosis | 44 6% | 13 4% | 31 7% | 9 10% | 9 7% | 3 3% | 2 2% | 22 6% | 16 7% | 12 6% | 8 5% | 8 4% | 4 15% | 8 9% | 5 6% | - * | - 1% | 3 4% | 3 5% | 6 6% | 10 10% | - ** | 2 3% | 3 12% | | | | |
| Post-surgical pain | 37 5% | 23 7% | 14 3% | 3 4% | 11 9% | 6 6% | 4 4% | 13 4% | 12 6% | 10 5% | 4 3% | 10 5% | 2 6% | 2 3% | 2 5% | 4 6% | 1 1% | 3 4% | 3 5% | 3 4% | 3 8% | 1 5% | 5 8% | - ** | | | | |
| Stenosis | 23 3% | 15 4% | 8 2% | 3 3% | 5 4% | 5 5% | 2 2% | 8 2% | 11 5% | 6 3% | 2 1% | 5 3% | 1 2% | 2 2% | 1 1% | 2 3% | - * | 4 5% | 1 2% | 2 3% | 7 7% | 2 7% | 1 2% | - ** | | | | |
| The chronic pain was for something else (please specify) | 126 16% | 46 14% | 78 18% | 7 8% | 10 17% | 17 18% | 32 28% | 60 18% | 34 16% | 44 21% | 16 11% | 32 16% | 3 10% | 13 14% | 10 13% | 8 12% | 10 19% | 16 21% | 14 23% | 18 20% | 16 16% | 7 23% | 10 15% | 1 7% | | | | |
| Don't know | 9 1% | 5 1% | 4 1% | 1 1% | 7 6% | 1 1% | - * | - * | 4 2% | 1 1% | 3 2% | 1 1% | - * | 1 1% | 1 1% | 1 2% | - * | - 3% | 2 3% | 3 3% | 1 1% | 1 2% | - ** | - ** | | | | |
| Prefer not to answer | 16 2% | 7 2% | 9 2% | - * | 1 1% | 5 5% | 4 3% | 5 2% | 4 2% | 7 3% | 2 1% | 3 1% | 1 2% | 2 2% | 1 1% | - * | - 4% | 3 1% | 1 2% | 2 2% | 1 1% | - ** | 6 9% | - ** | | | | |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions (S/N): A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X Minimum Base: 30(**) Small Base: 100(*)

ColumnMeans (S/N): A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X Minimum Base: 30(**) Small Base: 100(*)

21-087515-10 - 9th March 2022 - 14th March 2022
PUBLIC
BRC - Chronic Pain Survey
All UK adults aged 16-75

Q10. Which, if any, types of treatment are you currently taking/ receiving for this chronic pain?

All who currently experience chronic pain

| | Gender | | | | Age | | | | Social Grade | | | | Region | | | | | | | | | | | |
|---|--------|------|--------|-------|-------|-------|-------|-------|--------------|-----|-----|-----|------------|------------|--------------------------|---------------|---------------|-----------------|------------|------------|----------------|-------|----------|------------------|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | A8 | C1 | C2 | DE | North East | North West | Yorkshire and Humberside | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 1125 | 509 | 607 | 133 | 183 | 173 | 210 | 426 | 492 | 334 | 94 | 205 | 44 | 133 | 102 | 99 | 80 | 116 | 93 | 126 | 146 | 49 | 105 | 32 |
| Weighted base | 1135 | 513 | 613 | 127 | 192 | 167 | 190 | 460 | 302 | 319 | 217 | 288 | 45 | 132 | 110 | 102 | 86 | 115 | 94 | 134 | 143 | 45 | 103 | 27 |
| Opioids, such as codine, morphine, tramadol, oxycodone, buprenorphine, fentanyl, etc. | 272 | 106 | 164 | 11 | 34 | 34 | 53 | 140 | 65 | 72 | 46 | 89 | 15 | 22 | 26 | 22 | 22 | 34 | 26 | 37 | 24 | 11 | 23 | 9 |
| | 24% | 21% | 27% | 8% | 18% | 21% | 28% | 30% | 21% | 23% | 21% | 30% | 34% | 17% | 24% | 22% | 25% | 29% | 28% | 28% | 17% | 23% | 23% | 35% |
| | | | | 0 | 0 | 0 | 16 | 100 | | | | | | | | | | 100* | | | | | | |
| Paracetamol | 396 | 183 | 215 | 45 | 67 | 57 | 63 | 164 | 106 | 112 | 63 | 114 | 18 | 46 | 50 | 40 | 34 | 18 | 33 | 29 | 45 | 16 | 38 | 9 |
| | 35% | 32% | 38% | 35% | 35% | 34% | 33% | 36% | 35% | 35% | 29% | 38% | 40% | 35% | 46% | 39% | 39% | 33% | 35% | 22% | 31% | 36% | 37% | 35% |
| | | | | | | | | | * | | | | 1* | 1 | 10* | 1* | 1* | * | * | * | | | 1* | ** |
| Anti-inflammatories, such as ibuprofen, naproxen, celecoxib, duloxetine, etc. | 355 | 159 | 195 | 28 | 47 | 57 | 71 | 152 | 106 | 106 | 61 | 83 | 14 | 36 | 38 | 35 | 21 | 34 | 31 | 37 | 47 | 17 | 35 | 10 |
| | 31% | 31% | 32% | 22% | 25% | 34% | 38% | 33% | 33% | 33% | 28% | 28% | 32% | 27% | 35% | 34% | 24% | 30% | 33% | 28% | 33% | 37% | 34% | 38% |
| | | | | | | 0 | 0 | 0 | | | * | | * | | * | * | * | * | * | * | * | * | * | ** |
| Antidepressants, such as amitriptyline, nortriptyline, duloxetine, etc. | 217 | 84 | 133 | 26 | 35 | 40 | 35 | 80 | 49 | 57 | 36 | 75 | 8 | 15 | 21 | 17 | 21 | 24 | 17 | 23 | 33 | 10 | 19 | 8 |
| | 19% | 16% | 22% | 21% | 18% | 24% | 19% | 17% | 16% | 18% | 17% | 23% | 19% | 12% | 20% | 17% | 25% | 21% | 18% | 17% | 23% | 21% | 18% | 30% |
| | | | | | | | | | | | | | | | * | * | * | * | * | * | * | * | * | * |
| Physiotherapy | 154 | 74 | 79 | 18 | 34 | 27 | 29 | 46 | 52 | 47 | 12 | 43 | 8 | 17 | 12 | 12 | 5 | 22 | 12 | 18 | 28 | 3 | 14 | 3 |
| | 14% | 14% | 13% | 15% | 18% | 16% | 15% | 10% | 17% | 15% | 5% | 15% | 17% | 13% | 11% | 12% | 6% | 19% | 13% | 13% | 19% | 7% | 13% | 13% |
| | | | | | H | | | | K | K | * | * | * | * | * | * | 0* | * | * | Q | * | * | * | ** |
| Gabapentinoids, such as pregabalin, gabapentin etc. | 119 | 49 | 69 | 10 | 20 | 21 | 21 | 48 | 30 | 26 | 20 | 43 | 9 | 17 | 14 | 14 | 10 | 12 | 6 | 4 | 13 | 4 | 15 | 1 |
| | 10% | 10% | 11% | 8% | 10% | 13% | 11% | 10% | 10% | 8% | 9% | 14% | 13% | 13% | 13% | 14% | 12% | 10% | 6% | 3% | 9% | 9% | 15% | 3% |
| | | | | | | | | | | | | | | | | | | | * | | | | | ** |
| Support to improve sleep | 94 | 41 | 56 | 19 | 21 | 21 | 12 | 24 | 28 | 22 | 18 | 29 | 2 | 8 | 8 | 10 | 2 | 5 | 8 | 10 | 19 | 5 | 15 | 3 |
| | 8% | 8% | 9% | 15% | 11% | 12% | 6% | 5% | 9% | 7% | 8% | 10% | 5% | 6% | 8% | 9% | 3% | 5% | 9% | 8% | 13% | 12% | 15% | 10% |
| | | | | GH | H | H | | | | * | * | * | * | * | * | * | * | * | * | 0R | * | | NGR* | ** |
| Steroid injections | 90 | 35 | 56 | 6 | 16 | 21 | 14 | 35 | 31 | 17 | 17 | 25 | 6 | 8 | 8 | 11 | 9 | 4 | 5 | 10 | 15 | 4 | 6 | 4 |
| | 8% | 7% | 9% | 5% | 8% | 12% | 7% | 8% | 10% | 5% | 8% | 8% | 14% | 6% | 7% | 10% | 10% | 4% | 5% | 7% | 10% | 10% | 6% | 14% |
| | | | | | | 0 | | | | | | | * | * | * | * | * | * | * | * | * | * | * | * |
| Suscept to be more physically active | 79 | 38 | 40 | 7 | 19 | 15 | 8 | 30 | 33 | 23 | 13 | 30 | 1 | 9 | 8 | 12 | 6 | 5 | 7 | 8 | 10 | 2 | 8 | 3 |
| | 7% | 7% | 7% | 6% | 10% | 9% | 4% | 6% | 11% | 7% | 6% | 3% | 2% | 7% | 8% | 11% | 7% | 5% | 7% | 6% | 7% | 4% | 8% | 11% |
| | | | | | | | | | L | L | * | * | * | * | * | * | * | * | * | * | * | * | * | ** |
| Taking therapies, such as cognitive behavioural therapy, counselling, trauma therapy etc. | 72 | 38 | 34 | 15 | 24 | 17 | 9 | 7 | 22 | 15 | 11 | 24 | 4 | 4 | 4 | 3 | 4 | 9 | 6 | 10 | 16 | 4 | 6 | 1 |
| | 6% | 7% | 6% | 12% | 13% | 10% | 5% | 1% | 7% | 5% | 5% | 8% | 9% | 3% | 4% | 2% | 4% | 8% | 7% | 8% | 11% | 10% | 6% | 3% |
| | | | | GH | H | H | | | | | | | * | * | * | * | * | * | * | * | * | * | * | ** |
| Chiropractic or osteopathic support | 61 | 31 | 30 | 11 | 17 | 11 | 8 | 12 | 25 | 11 | 11 | 14 | 1 | 8 | 3 | 8 | 3 | 11 | 5 | 4 | 10 | 1 | 5 | 2 |
| | 5% | 6% | 5% | 8% | 9% | 7% | 5% | 3% | 8% | 3% | 5% | 5% | 2% | 6% | 3% | 7% | 3% | 10% | 5% | 3% | 7% | 3% | 4% | 6% |
| | | | | H | H | H | | | J | * | * | * | * | * | * | * | * | * | * | * | * | * | * | ** |
| Acupuncture | 46 | 26 | 20 | 11 | 10 | 8 | 7 | 9 | 19 | 11 | 5 | 11 | - | 5 | 6 | 2 | 1 | 8 | 1 | 6 | 12 | 2 | 3 | * |
| | 4% | 5% | 3% | 9% | 5% | 5% | 4% | 2% | 6% | 3% | 2% | 4% | - | 3% | 6% | 2% | 1% | 7% | 1% | 5% | 8% | 3% | 3% | 2% |
| | | | | H | | | | | | | | | | * | * | * | * | * | * | * | * | * | * | ** |
| Other treatment (please specify) | 151 | 58 | 94 | 8 | 14 | 18 | 14 | 18 | 25 | 48 | 36 | 41 | 2 | 26 | 19 | 4 | 20 | 15 | 16 | 18 | 17 | 5 | 9 | 1 |
| | 13% | 11% | 15% | 6% | 7% | 11% | 7% | 21% | 8% | 15% | 17% | 14% | 4% | 19% | 17% | 4% | 23% | 13% | 17% | 13% | 12% | 11% | 9% | 2% |
| | | | | | | | DEFG | | I | 1* | I | * | | NPW | P* | * | NPW* | P* | P* | P* | P* | * | * | ** |
| I have not had/ received any treatment for this pain | 101 | 58 | 40 | 7 | 12 | 19 | 23 | 41 | 30 | 37 | 14 | 20 | 4 | 15 | 5 | 12 | 10 | 9 | 6 | 15 | 13 | 5 | 5 | 1 |
| | 9% | 11% | 7% | 5% | 6% | 11% | 12% | 9% | 10% | 12% | 6% | 7% | 8% | 11% | 4% | 12% | 12% | 8% | 6% | 11% | 9% | 12% | 5% | 5% |
| | | | | C | | | | | | | | | * | * | * | * | * | * | * | * | * | * | * | ** |
| Don't know | 9 | 5 | 5 | 4 | 4 | 2 | - | - | 2 | 1 | 3 | 3 | - | 2 | 1 | 1 | - | - | - | 3 | 2 | - | - | - |
| | 1% | 1% | 1% | 1% | 3% | 2% | 1% | - | 1% | * | 1% | 1% | - | 2% | 1% | 1% | - | - | - | 2% | 1% | - | - | - |
| | | | | GH | H | | | | | * | * | * | * | * | * | * | * | * | * | * | * | * | * | ** |
| Prefer not to answer | 20 | 12 | 8 | - | 5 | 8 | 4 | 3 | 3 | 6 | 7 | 4 | - | 4 | 2 | 3 | - | 2 | - | 1 | 3 | - | 5 | 1 |
| | 2% | 2% | 1% | - | 3% | 5% | 2% | 1% | 1% | 2% | 3% | 1% | - | 3% | 2% | 3% | - | 2% | - | 1% | 2% | - | 4% | 2% |
| | | | | | | | | | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | ** |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|---|------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| NET: Exclusively opioids | 52 | 29 | 23 | 2 | 8 | 4 | 10 | 28 | 9 | 12 | 20 | 11 | 1 | 6 | 5 | 3 | 3 | 4 | 5 | 15 | 3 | 1 | 4 | 3 |
| | 5% | 6% | 4% | 2% | 4% | 2% | 5% | 6% | 3% | 4% | 9% | 4% | 2% | 5% | 4% | 3% | 3% | 3% | 11% | 2% | 1% | 4% | 13% | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| NET: Exclusively gabapentinoids | 16 | 9 | 6 | 5 | 3 | 2 | 3 | 3 | 5 | 5 | 1 | 6 | 1 | 4 | 2 | * | * | 1 | 1 | 1 | 3 | - | 2 | - |
| | 1% | 2% | 1% | 4% | 2% | 1% | 2% | 1% | 2% | 1% | * | 2% | 2% | 3% | 2% | * | 2% | * | 1% | 1% | 2% | - | 2% | - |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| NET: Exclusively opioids or gabapentinoids | 79 | 43 | 35 | 7 | 12 | 6 | 14 | 40 | 15 | 18 | 28 | 18 | 4 | 11 | 7 | 5 | 6 | 5 | 6 | 16 | 6 | 1 | 9 | 3 |
| | 7% | 8% | 6% | 5% | 6% | 4% | 7% | 9% | 5% | 6% | 13% | 6% | 10% | 8% | 7% | 5% | 7% | 5% | 6% | 12% | 4% | 1% | 9% | 13% |
| | | | | | | | | | | | U* | * | * | * | * | * | * | * | * | U* | * | * | * | ** |
| NET: Any treatment, excl. opioids | 733 | 334 | 396 | 106 | 138 | 104 | 110 | 275 | 202 | 202 | 148 | 181 | 26 | 88 | 77 | 63 | 55 | 69 | 62 | 77 | 101 | 29 | 70 | 15 |
| | 65% | 65% | 65% | 83% | 72% | 63% | 58% | 60% | 67% | 63% | 68% | 61% | 58% | 67% | 70% | 62% | 63% | 60% | 66% | 58% | 70% | 65% | 68% | 57% |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| NET: Any treatment, excl. opioids or gabapentinoids | 669 | 303 | 363 | 98 | 123 | 93 | 99 | 256 | 181 | 188 | 137 | 163 | 22 | 76 | 71 | 63 | 55 | 64 | 59 | 74 | 92 | 28 | 62 | 15 |
| | 59% | 59% | 59% | 77% | 64% | 56% | 52% | 56% | 60% | 60% | 59% | 63% | 55% | 40% | 58% | 55% | 56% | 56% | 62% | 55% | 65% | 62% | 61% | 57% |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| NET: Any treatment | 1005 | 439 | 560 | 117 | 172 | 138 | 163 | 415 | 267 | 274 | 193 | 270 | 41 | 111 | 103 | 86 | 76 | 103 | 89 | 115 | 125 | 40 | 93 | 25 |
| | 89% | 86% | 91% | 92% | 90% | 83% | 86% | 88% | 86% | 88% | 89% | 91% | 92% | 84% | 94% | 84% | 88% | 90% | 94% | 86% | 87% | 88% | 91% | 92% |
| | | | | | | | | | | | | | | | | | | | | | | | | |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Output format used

Column headers (D1) A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X Minimum base: 387** (Small base: 100**)

Column headers (D2) A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X Minimum base: 387** (Small base: 100**)

21-087515-10 - 9th March 2022 - 14th March 2022

PUBLIC
BRC - Chronic Pain Survey
All UK adults aged 16-75
Q11. You mentioned that you are currently taking opioids for this chronic pain. Which of the following opioids (or types of opioid) are you currently taking?
All currently taking opioids for chronic pain

| | Gender | | | Age | | | | | Social Grade | | | | Region | | | | | | | | | | | |
|--|------------|-----------|------------|----------|-----------|-----------|-----------|-----------|--------------|-----------|-----------|-----------|------------|------------|--------------------------|---------------|---------------|-----------------|------------|------------|----------------|----------|-----------|------------------|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | A8 | C1 | C2 | DE | North East | North West | Yorkshire and the Humber | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 258 | 105 | 150 | 14 | 30 | 32 | 56 | 126 | 105 | 77 | 18 | 58 | 15 | 24 | 20 | 20 | 17 | 34 | 23 | 29 | 28 | 14 | 22 | 12 |
| Weighted base | 272 | 106 | 164 | 11 | 34 | 34 | 53 | 140 | 65 | 72 | 46 | 80 | 15 | 22 | 26 | 22 | 22 | 34 | 26 | 37 | 24 | 11 | 23 | 9 |
| Strong Opioids | 129 47% | 55 51% | 72 43% | 7 6% | 19 55% | 22 64% | 25 47% | 56 40% | 44 67% | 31 43% | 16 44% | 37 50% | 30 40% | 11 14% | 16 24% | 9 13% | 7 10% | 17 24% | 9 13% | 13 18% | 18 24% | 4 6% | 8 11% | 5 7% |
| Tramadol (i.e. Tramadol hydrochloride) | 64 23% | 29 27% | 34 21% | 3 28% | 7 22% | 11 33% | 12 22% | 30 22% | 24 37% | 18 25% | 5 12% | 16 21% | 5 18% | 6 39% | 4 22% | 3 21% | 4 18% | 3 12% | 11 27% | 7 12% | 5 12% | 8 33% | 2 22% | 6 27% |
| Morphine | 36 13% | 12 12% | 24 14% | 1 9% | 3 9% | 8 23% | 8 11% | 16 11% | 9 14% | 9 12% | 8 17% | 10 13% | 4 5% | 2 14% | 8 12% | 2 10% | 2 10% | 5 16% | 1 15% | 6 13% | 1 6% | 1 13% | 1 11% | 1 10% |
| Oxycodone (i.e. Oxycodone hydrochloride) | 19 7% | 16 15% | 3 2% | 4 28% | 4 10% | 5 16% | 4 6% | 3 2% | 11 17% | 1 2% | 3 6% | 4 5% | - | 1 4% | 4 15% | 1 6% | - | 3 8% | 1 3% | 3 8% | 5 19% | 1 7% | 1 2% | - |
| Hydrocodone (i.e. Hydrocodone hydrochloride) | 12 5% | 6 6% | 6 4% | 2 18% | 2 6% | 3 9% | 3 4% | 1 1% | 7 10% | 2 2% | - | 4 5% | 1 1% | 2 14% | 3 12% | - | - | 1 2% | 1 3% | 1 4% | 2 10% | - | - | 1 10% |
| Buprenorphine | 12 4% | 5 5% | 7 4% | 2 20% | 1 3% | 4 10% | 1 1% | 4 3% | 6 9% | 3 4% | - | 3 4% | - | 2 14% | 1 10% | 1 2% | - | 1 3% | - | 2 6% | 4 10% | 1 7% | - | 1 8% |
| Alfentanil, fentanyl or remifentanyl | 11 4% | 9 8% | 2 1% | 2 14% | 1 3% | 3 8% | 3 4% | 2 1% | 5 8% | 1 1% | - | 5 6% | - | 2 14% | - | 1 6% | 1 3% | 2 6% | - | - | 5 19% | - | - | 1 2% |
| Hydroxycodone (i.e. Hydroxycodone hydrochloride) | 9 3% | 5 5% | 4 2% | 1 12% | 1 3% | 5 14% | 1 1% | - | 7 10% | 2 2% | - | - | 1 1% | 1 1% | 1 1% | 1 3% | 1 3% | - | 1 3% | 1 3% | 2 10% | 1 7% | - | 1 8% |
| Pentazocine | 8 3% | 6 6% | 2 1% | * 20% | 3 7% | 2 6% | 1 1% | 1 1% | 8 11% | - | - | - | - | 1 14% | - | - | 2 10% | 1 3% | 1 3% | - | 3 13% | - | - | - |
| Urgenpocaine (i.e. Urgenpocaine hydrochloride) | 8 3% | 5 5% | 3 2% | 2 16% | 1 3% | 3 8% | 1 1% | 1 1% | 5 7% | 1 1% | - | 1 1% | - | 1 14% | 3 10% | 1 3% | 1 3% | - | - | - | 2 10% | - | - | - |
| Pethidine (i.e. Pethidine hydrochloride) | 6 2% | 6 5% | 1 1% | 1 8% | 2 5% | 3 8% | 1 1% | - | 6 9% | 1 1% | - | - | - | * 14% | 1 10% | - | - | 1 3% | - | 1 2% | 4 15% | - | - | - |
| Tasentanil | 6 2% | 4 4% | 2 1% | 1 10% | 1 3% | 2 6% | 1 1% | 1 1% | 6 9% | - | - | - | - | 1 14% | 1 10% | - | - | - | 1 3% | 2 6% | 8 33% | - | - | - |
| Weak Opioids | 170 63% | 66 62% | 102 60% | 8 6% | 25 72% | 21 64% | 33 24% | 84 60% | 32 49% | 51 70% | 31 43% | 57 75% | 5 7% | 13 19% | 18 26% | 16 22% | 14 19% | 20 24% | 20 24% | 24 55% | 12 50% | 8 33% | 16 33% | 5 40% |
| Codine (i.e. Codine ethiohate) | 145 53% | 53 50% | 90 55% | 4 34% | 19 56% | 17 49% | 27 20% | 78 56% | 26 40% | 48 66% | 25 33% | 46 59% | 5 7% | 13 19% | 11 16% | 16 22% | 11 14% | 17 20% | 20 24% | 21 57% | 9 38% | 7 29% | 10 21% | 5 40% |
| Dihydrocodone tartrate | 22 8% | 10 9% | 12 7% | 4 34% | 2 6% | 3 9% | 5 4% | 7 5% | 2 3% | 2 3% | 10 14% | - | - | - | 2 10% | - | 2 3% | 4 10% | - | 3 8% | 3 12% | 1 4% | 6 13% | - |
| Mettastain | 13 5% | 10 9% | 3 2% | 2 14% | 6 18% | 5 14% | - | - | 6 9% | 2 3% | 3 4% | 1 1% | - | * 14% | 6 24% | - | - | - | 1 3% | 1 3% | 4 16% | - | - | - |
| Other opioid treatment | 11 12% | 11 10% | 19 11% | 1 8% | 1 2% | 1 3% | 22 16% | 5 4% | 11 15% | 2 3% | 13 18% | - | 3 4% | 3 19% | 4 16% | 4 18% | 2 3% | 4 10% | 2 5% | 3 8% | 5 19% | 1 4% | 4 9% | 2 17% |
| Don't know | 4 1% | 3 3% | 1 1% | - | * 3% | - | 3 2% | - | * 1% | 1 1% | - | 3 4% | - | 3 19% | * 14% | - | - | 1 3% | - | - | 1 4% | - | 1 3% | - |
| Prefer not to answer | 1 * | - | 1 1% | - | 1 3% | - | - | 1 1% | 1 1% | 1 1% | - | - | - | - | - | - | - | 1 3% | - | 1 2% | - | - | - | - |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|------------------------|------------|-----------|------------|----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|----------|-----------|----------|
| NET: Exclusive Weak | 116 43% | 42 40% | 74 45% | 4 38% | 13 39% | 9 25% | 24 45% | 66 47% | 18 27% | 32 44% | 27 40% | 39 44% | 4 7% | 9 14% | 8 10% | 10 13% | 10 12% | 15 17% | 14 16% | 21 55% | 5 21% | 6 58% | 12 53% | 3 31% |
| NET: Weak | 170 63% | 66 63% | 102 62% | 8 72% | 25 70% | 21 63% | 33 24% | 84 60% | 32 49% | 51 70% | 31 43% | 57 75% | 5 7% | 13 19% | 18 26% | 16 22% | 14 19% | 20 24% | 20 24% | 24 55% | 12 50% | 8 33% | 16 33% | 5 40% |
| NET: Exclusive Strong | 81 30% | 33 32% | 47 28% | 3 28% | 7 20% | 12 34% | 17 11% | 43 31% | 13 19% | 29 40% | 16 22% | 23 29% | 7 9% | 6 38% | 3 12% | 6 23% | 3 10% | 12 17% | 9 20% | 11 25% | 3 12% | 5 24% | 4 21% | 4 45% |
| NET: Strong | 129 47% | 55 52% | 72 44% | 7 62% | 19 55% | 22 64% | 25 47% | 56 40% | 44 67% | 31 43% | 16 44% | 37 50% | 30 40% | 11 14% | 16 24% | 9 13% | 7 10% | 17 24% | 9 13% | 13 18% | 18 24% | 4 6% | 8 11% | 5 7% |
| NET: Mix (weak/strong) | 45 17% | 21 20% | 24 15% | 4 34% | 12 35% | 10 30% | 9 10% | 11 8% | 14 22% | 15 21% | 3 4% | 13 18% | 1 1% | 4 19% | 3 10% | 3 13% | 2 5% | 5 12% | 4 9% | 3 7% | 7 29% | 2 10% | 2 8% | 1 8% |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlay Terminal used
CustomReportName (EN) A-B-C-D-E-F-G-H-I-J-K-L-M-N-O-P-Q-R-S-T-U-V-W-X-Y-Z Minimum Base: 30773 (Small Base: 10077)
CustomReportName (EN) A-B-C-D-E-F-G-H-I-J-K-L-M-N-O-P-Q-R-S-T-U-V-W-X-Y-Z Minimum Base: 30773 (Small Base: 10077)

21-087515-10 - 9th March 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey
All UK adults aged 16-75

Q12. You mentioned that you are currently taking opioids for this chronic pain. When did you first start taking them?

All currently taking opioids for chronic pain

| | Gender | | | Age | | | | | Social Grade | | | | | Region | | | | | | | | | | | | |
|-------------------------------|--------|------|--------|-------|-------|-------|-------|-------|--------------|-----|-----|-----|------------|------------|--------------------------|---------------|---------------|-----------------|------------|------------|----------------|-------|----------|------------------|--|--|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | A8 | C1 | C2 | DE | North East | North West | Yorkshire and Humberside | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland | | |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) | | |
| Unweighted base | 258 | 105 | 150 | 14 | 30 | 32 | 56 | 126 | 105 | 77 | 18 | 58 | 15 | 24 | 20 | 20 | 17 | 34 | 23 | 29 | 28 | 14 | 22 | 12 | | |
| Weighted base | 272 | 106 | 164 | 11 | 34 | 34 | 53 | 140 | 65 | 72 | 46 | 89 | 15 | 22 | 26 | 22 | 22 | 34 | 26 | 37 | 24 | 11 | 23 | 9 | | |
| In the last 4 weeks | 17 | 4 | 13 | 2 | 4 | 1 | - | 9 | 3 | 3 | - | 10 | - | 1 | 1 | 2 | - | 2 | 1 | 5 | 3 | - | - | 3 | | |
| | 6% | 3% | 8% | 18% | 13% | 4% | - | 7% | 5% | 5% | - | 12% | - | 4% | 3% | 11% | - | 6% | 3% | 12% | 14% | - | - | 27% | | |
| | * | * | ** | ** | ** | ** | * | * | * | * | ** | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | | |
| Approximately 2-3 months ago | 14 | 6 | 7 | 2 | 4 | 1 | 6 | 1 | 5 | 7 | - | 3 | - | 3 | - | 1 | - | 4 | 1 | 1 | 2 | 1 | 2 | - | | |
| | 5% | 6% | 4% | 19% | 11% | 4% | 12% | * | 8% | 9% | - | 3% | - | 13% | - | 4% | - | 12% | 4% | 2% | 8% | 7% | 8% | - | | |
| | * | * | ** | ** | ** | ** | ** | * | * | * | ** | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | | |
| Approximately 4-6 months ago | 24 | 11 | 13 | 2 | 3 | 7 | 5 | 7 | 6 | 7 | 3 | 7 | 2 | 1 | 6 | 2 | * | 3 | 1 | 3 | 3 | 1 | 4 | - | | |
| | 9% | 11% | 8% | 18% | 10% | 20% | 9% | 5% | 10% | 10% | 7% | 8% | 10% | 3% | 23% | 10% | 2% | 8% | 2% | 7% | 12% | 10% | 16% | - | | |
| | * | * | ** | ** | ** | ** | * | * | * | * | * | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | | |
| Approximately 7-12 months ago | 13 | 8 | 5 | 1 | 3 | 2 | 1 | 7 | 6 | 5 | 2 | - | 3 | 1 | 1 | - | 2 | 2 | 2 | 1 | 1 | - | 1 | - | | |
| | 5% | 8% | 3% | 7% | 8% | 6% | 3% | 5% | 9% | 7% | 5% | - | 18% | 3% | 3% | - | 8% | 6% | 7% | 3% | 5% | - | 5% | - | | |
| | * | * | ** | ** | ** | ** | * | * | L | * | * | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | | |
| Approximately 1-2 years ago | 22 | 6 | 16 | 2 | 3 | 1 | 6 | 10 | 9 | 4 | - | 9 | 1 | 2 | 5 | 2 | 3 | 4 | 2 | 1 | 1 | 1 | - | 1 | | |
| | 8% | 6% | 10% | 23% | 9% | 4% | 11% | 7% | 14% | 6% | - | 10% | 8% | 18% | 10% | 14% | 11% | 9% | 2% | 4% | 5% | - | 12% | 8% | | |
| | * | * | ** | ** | ** | ** | * | * | * | * | * | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | | |
| Approximately 2-3 years ago | 29 | 11 | 18 | 1 | 6 | 1 | 4 | 17 | 5 | 8 | 10 | 5 | 2 | 1 | 1 | 1 | 9 | 2 | - | 9 | 3 | 2 | - | - | | |
| | 11% | 10% | 11% | 5% | 18% | 4% | 8% | 12% | 8% | 12% | 22% | 6% | 10% | 6% | 3% | 4% | 40% | 6% | - | 23% | 12% | 20% | - | - | | |
| | * | * | ** | ** | ** | ** | * | * | * | * | * | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | | |
| Approximately 3-5 years ago | 32 | 21 | 11 | * | 5 | 5 | 9 | 12 | 7 | 9 | 7 | 10 | 1 | 8 | - | 3 | 1 | 3 | 6 | 5 | 3 | - | 2 | 2 | | |
| | 12% | 19% | 7% | 4% | 15% | 15% | 17% | 9% | 10% | 12% | 15% | 11% | 6% | 34% | - | 13% | 3% | 8% | 22% | 12% | 10% | - | 9% | 25% | | |
| | C* | * | ** | ** | ** | ** | * | * | * | * | * | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | | |
| Approximately 5-10 years ago | 61 | 14 | 47 | - | 1 | 7 | 11 | 44 | 10 | 9 | 18 | 24 | 2 | 2 | 10 | 5 | 3 | 10 | 9 | 9 | 3 | 2 | 7 | - | | |
| | 23% | 13% | 29% | - | 2% | 19% | 20% | 31% | 16% | 13% | 40% | 27% | 11% | 8% | 39% | 24% | 13% | 28% | 34% | 23% | 14% | 16% | 32% | - | | |
| | * | 8 | ** | ** | ** | ** | * | * | * | * | * | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | | |
| More than 10 years ago | 51 | 22 | 27 | 1 | 4 | 7 | 9 | 30 | 12 | 18 | 2 | 19 | 4 | 3 | 3 | 5 | 3 | 5 | 3 | 6 | 5 | 4 | 6 | 3 | | |
| | 19% | 21% | 16% | 6% | 13% | 19% | 18% | 21% | 18% | 25% | 5% | 21% | 26% | 13% | 11% | 24% | 13% | 15% | 13% | 16% | 21% | 41% | 25% | 36% | | |
| | * | * | ** | ** | ** | ** | * | * | * | * | * | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | | |
| Don't know | 7 | 3 | 4 | - | 1 | 2 | 1 | 4 | 1 | 1 | 3 | 3 | 2 | 2 | - | - | 1 | - | 1 | - | - | - | 2 | - | | |
| | 3% | 3% | 3% | - | 2% | 4% | 3% | 3% | 1% | 1% | 7% | 3% | 11% | 7% | 5% | 11% | 7% | 5% | 3% | - | - | - | 6% | - | | |
| | * | ** | ** | * | ** | ** | * | * | * | * | * | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | | |
| Prefer not to answer | 1 | - | 1 | - | - | - | - | 1 | 1 | - | - | - | - | - | - | - | - | - | 1 | - | - | - | - | - | | |
| | * | - | * | - | - | - | - | 8 | 1% | - | - | - | - | - | - | - | - | - | 2% | - | - | - | - | - | | |
| | * | * | ** | ** | ** | ** | * | * | * | * | * | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | | |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|-------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| NET: At least a year ago | 196 | 73 | 120 | 4 | 19 | 21 | 39 | 112 | 43 | 49 | 37 | 66 | 9 | 16 | 19 | 17 | 18 | 23 | 20 | 28 | 15 | 9 | 15 | 7 |
| | 72% | 69% | 73% | 38% | 56% | 61% | 74% | 80% | 67% | 68% | 81% | 74% | 61% | 71% | 71% | 75% | 84% | 68% | 78% | 75% | 61% | 82% | 65% | 73% |
| | * | ** | ** | ** | * | ** | * | * | * | * | * | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** |
| NET: 2-3 years ago or longer | 173 | 67 | 104 | 2 | 16 | 20 | 34 | 102 | 34 | 45 | 37 | 57 | 8 | 14 | 14 | 15 | 15 | 19 | 18 | 28 | 14 | 8 | 15 | 6 |
| | 64% | 63% | 64% | 15% | 47% | 58% | 63% | 73% | 52% | 62% | 81% | 64% | 53% | 60% | 54% | 66% | 70% | 58% | 69% | 74% | 57% | 77% | 65% | 61% |
| | * | ** | ** | ** | ** | * | * | * | * | ** | * | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** |
| NET: 3-5 years ago or longer | 144 | 56 | 86 | 1 | 10 | 18 | 29 | 86 | 29 | 36 | 27 | 52 | 7 | 12 | 13 | 14 | 6 | 17 | 18 | 19 | 11 | 6 | 15 | 6 |
| | 53% | 53% | 52% | 10% | 29% | 53% | 55% | 61% | 44% | 50% | 59% | 58% | 43% | 55% | 51% | 61% | 29% | 51% | 69% | 51% | 45% | 57% | 65% | 61% |
| | * | ** | ** | ** | * | ** | * | * | * | * | * | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** |
| NET: 5-10 years ago or longer | 112 | 36 | 74 | 1 | 5 | 13 | 20 | 73 | 22 | 28 | 20 | 43 | 6 | 5 | 13 | 11 | 6 | 15 | 12 | 14 | 9 | 6 | 13 | 3 |
| | 41% | 34% | 45% | 6% | 15% | 38% | 38% | 52% | 34% | 38% | 44% | 48% | 37% | 21% | 51% | 48% | 26% | 44% | 46% | 39% | 35% | 57% | 56% | 36% |
| | * | * | ** | ** | ** | ** | * | * | * | * | ** | * | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** | ** |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used
ColumnProportions (SN): A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X Minimum Base: 30(**) Small Base: 100(*)
ColumnMeans (SN): A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X Minimum Base: 30(**) Small Base: 100(*)

21-087515-10 - 9th March 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q13. During the course of this chronic pain, you may have had contact with one or more healthcare professionals about your chronic pain. Thinking about all of the care that you have received from the health care professionals for this chronic pain, how would you rate it overall?

All with chronic pain and had contact with health professional (past 12 months)

| | Gender | | | Age | | | | | Social Grade | | | | Region | | | | | | | | | | | |
|-----------------------|------------|------------|------------|------------------|-----------|-------------------|-----------------|-----------------|----------------|-----------|-----------------|-----------|-----------------|-----------------|----------------------|-----------------|----------------|------------------|------------------|-----------------|----------------|----------------|-----------------|------------------|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | AB | C1 | C2 | DE | North East | North West | Yorkshire and Humber | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 764 | 340 | 420 | 101 | 146 | 123 | 133 | 261 | 351 | 211 | 63 | 139 | 32 | 94 | 70 | 66 | 54 | 81 | 58 | 79 | 116 | 29 | 66 | 19 |
| Weighted base | 756 | 334 | 418 | 98 | 152 | 113 | 119 | 275 | 216 | 196 | 142 | 203 | 29 | 95 | 73 | 65 | 57 | 85 | 56 | 75 | 113 | 27 | 66 | 16 |
| Excellent | 96 13% | 48 14% | 48 12% | 20 20% GH* | 24 16% | 18 16% * | 9 8% | 25 9% | 35 16% J | 19 10% | 16 11% * | 26 13% | 3 9% ** | 13 13% * | 7 9% * | 3 5% * | 7 12% * | 12 14% * | 14 24% OP* | 13 17% P* | 15 13% * | 3 10% ** | 7 11% * | 1 6% ** |
| Very good | 131 17% | 59 18% | 70 17% | 15 15% * | 26 17% | 29 26% GH* | 16 13% | 45 16% | 51 24% L | 34 18% | 19 14% * | 26 13% | 4 13% ** | 18 18% * | 15 21% * | 7 11% * | 5 10% * | 13 16% * | 12 21% * | 11 15% * | 23 20% * | 6 22% ** | 11 17% * | 5 33% ** |
| Fairly good | 257 34% | 114 34% | 140 34% | 36 37% P* | 43 28% | 25 22% * | 51 43% EF | 102 37% F | 58 27% | 66 34% | 66 47% I* | 67 33% | 11 39% ** | 29 31% * | 22 30% * | 23 36% * | 18 32% * | 38 45% ST* | 12 21% * | 21 27% * | 41 37% * | 9 32% ** | 28 42% 5* | 6 35% ** |
| Neither good nor poor | 115 15% | 45 13% | 70 17% | 13 13% * | 24 16% | 13 11% * | 20 17% * | 45 16% | 27 13% | 31 16% | 19 14% * | 37 18% | 5 17% ** | 15 15% * | 13 19% R* | 13 25% R* | 14 19% * | 6 7% * | 6 10% * | 12 16% * | 17 15% * | 1 4% ** | 10 15% * | 3 20% ** |
| Fairly poor | 77 10% | 37 11% | 41 10% | 6 6% * | 20 13% | 19 17% DGH* | 8 7% | 24 9% | 24 11% | 22 11% | 8 6% * | 23 11% | 2 7% ** | 7 7% * | 6 8% * | 6 10% W* | 4 8% W* | 8 9% * | 8 14% * | 11 15% * | 11 10% * | 7 27% ** | 5 8% * | 1 4% ** |
| Very poor | 48 6% | 17 5% | 30 7% | 1 1% * | 8 5% | 5 5% * | 11 10% D | 22 8% D | 13 6% | 12 6% | 6 4% * | 16 8% | 2 8% ** | 10 10% W* | 6 9% W* | 6 10% W* | 5 8% * | 7 8% * | 3 5% * | 3 4% * | 4 3% * | 1 2% ** | 1 1% * | * 2% ** |
| Terrible | 23 3% | 9 3% | 13 3% | 6 6% * | 5 4% | 2 2% * | 4 3% | 5 2% | 5 3% | 9 5% | 5 3% * | 3 2% | 1 3% ** | 1 1% * | 2 3% U* | 5 7% U* | 3 5% * | 1 1% * | 3 5% * | 3 4% * | 1 * * | 1 3% ** | 2 4% * | - - ** |
| Don't know | 5 1% | 3 1% | 2 * | 2 2% * | - - | 1 1% * | - - | 2 1% | 1 * | 1 1% | - * | 3 1% | 1 4% ** | 2 2% * | - * | - * | - * | - - | - - | 1 1% * | 1 1% * | - - | - - | - - ** |
| Prefer not to answer | 4 1% | 2 * | 3 1% | - - | 1 1% | - * | - - | 3 1% | 1 * | 1 * | 2 1% * | 2 1% | - - | 2 2% * | 1 1% * | 1 1% * | - * | - - | - - | - - | - - | - - | 2 2% ** | - - ** |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|---------------------|------------|------------|------------|----------------|-----------|----------------|-----------|------------|------------|------------|-----------------|------------|-----------------|----------------|----------------|----------------|----------------|------------------|----------------|----------------|-----------------|-----------------|----------------|-----------------|
| NET: Good/excellent | 484 64% | 221 66% | 259 62% | 71 72% * | 93 61% | 73 65% * | 76 64% | 172 63% | 144 67% | 120 61% | 101 72% * | 119 59% | 18 61% ** | 60 63% * | 44 60% * | 34 52% * | 30 54% * | 63 74% PQ* | 37 66% * | 45 59% * | 79 70% P* | 17 64% ** | 46 70% * | 12 74% ** |
| NET: Poor/terrible | 148 20% | 63 19% | 84 20% | 13 13% * | 34 22% | 26 23% * | 23 20% | 52 19% | 43 20% | 43 22% | 19 14% * | 43 21% | 5 18% ** | 18 18% * | 15 21% * | 18 27% * | 12 21% * | 16 19% * | 13 24% * | 18 23% * | 16 14% * | 9 32% ** | 8 12% * | 1 6% ** |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions [5%]- A,B/C,D/E,F/G,H,I/J/K/L,M/N/O/P/Q/R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)

ColumnMeans [5%]- A,B/C,D/E,F/G,H,I/J/K/L,M/N/O/P/Q/R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)

21-087515-10 - 9th March 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q14. And are you currently on a waiting list to start treatment, or booked in but yet to start any of the following treatments for this chronic pain?

All who currently experience chronic pain

| | Gender | | | Age | | | | | Social Grade | | | | Region | | | | | | | | | | | |
|--|------------|----------------|-----------------|------------------|------------------|-----------------|-------------------|-------------------|-----------------|-----------------|-----------------|------------|-------------------|----------------|--------------------------|------------------|-------------------|-------------------|------------------|-----------------|-------------------|------------------|-------------------|------------------|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | A8 | C1 | C2 | DE | North East | North West | Yorkshire and Humberside | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 1125 | 509 | 607 | 133 | 183 | 173 | 210 | 426 | 492 | 334 | 94 | 205 | 44 | 133 | 102 | 99 | 80 | 116 | 93 | 126 | 146 | 49 | 105 | 32 |
| Weighted base | 1135 | 513 | 613 | 127 | 192 | 167 | 190 | 460 | 302 | 319 | 217 | 298 | 45 | 132 | 110 | 102 | 86 | 115 | 94 | 134 | 143 | 45 | 103 | 27 |
| Surgery | 122 11% | 64 13% | 57 9% | 18 14% G | 33 17% GH | 24 14% GH | 11 6% | 37 8% | 46 15% JL | 27 8% | 24 11% * | 25 9% | 2 4% * | 23 17% O | 8 7% * | 9 9% * | 6 7% * | 12 11% * | 8 8% * | 16 12% * | 24 17% O | 4 8% * | 9 9% * | 2 9% ** |
| Pain management programme | 171 15% | 93 18% C | 78 13% | 33 26% GH | 54 28% GH | 35 21% GH | 13 7% | 37 8% | 58 19% J | 36 11% | 30 14% * | 47 16% | 11 25% OS* | 22 17% | 12 11% * | 13 13% | 13 15% * | 15 13% * | 9 10% * | 18 14% * | 35 25% ORST | 7 15% * | 14 14% * | 1 3% ** |
| Opioid withdrawal programme | 55 5% | 29 6% | 26 4% | 19 15% FGH | 16 8% GH | 11 7% GH | 2 1% | 6 1% | 20 7% JL | 8 3% | 17 8% J* | 9 3% | 5 11% NRW* | 3 2% | 3 2% * | 6 6% * | 3 4% * | 2 1% * | 4 4% * | 7 5% * | 13 9% NRW | 4 9% RW* | 1 1% * | 3 12% ** |
| Other – i.e. I'm waiting for another type of treatment | 165 15% | 65 13% | 97 16% | 22 17% | 26 14% | 23 14% | 24 12% | 70 15% | 47 15% | 43 14% | 21 10% * | 54 18% | 3 7% * | 22 17% W | 15 14% * | 23 23% MW* | 10 12% * | 15 14% * | 15 15% W* | 25 19% W* | 21 14% W | 4 10% * | 6 5% * | 5 21% ** |
| I am not currently on a waiting list or booked in to start treatment | 652 57% | 274 53% | 373 61% B | 43 34% | 67 35% DE | 84 50% DE | 138 72% DEF | 321 70% DEF | 160 53% | 200 63% I | 122 56% * | 171 57% | 24 53% * | 66 50% | 66 60% U* | 47 46% * | 57 66% NPU* | 74 65% NPU* | 61 64% PU* | 77 58% * | 64 45% | 31 68% PU* | 70 68% NPU* | 15 58% ** |
| Don't know | 41 4% | 26 5% C | 15 2% | 6 5% | 19 10% FGH | 4 2% | 5 2% | 7 2% | 6 2% | 11 4% | 11 5% * | 12 4% | 1 2% * | 3 2% | 11 10% NRSW* | 3 3% * | 3 4% * | 1 1% * | 1 2% * | 6 5% * | 7 5% | 2 4% * | 2 2% * | - - ** |
| Prefer not to answer | 15 1% | 8 2% | 7 1% | 2 2% | 2 1% | 5 3% | 3 2% | 3 1% | * * | 6 2% I | 5 2% * | 4 1% | 3 6% OGBST* | 3 2% | - - * | 4 4% * | - - * | 2 2% * | - - * | - - * | 1 1% | - - * | 2 2% * | - - ** |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|--------------------------|------------|------------|------------|------------------|------------------|-----------------|-----------|------------|-----------------|------------|----------------|------------|----------------|------------------|----------------|-------------------|----------------|----------------|----------------|----------------|---------------------|----------------|----------------|-----------------|
| NET: On any kind of list | 427 38% | 205 40% | 218 36% | 76 60% FGH | 103 54% GH | 74 45% GH | 45 24% | 129 28% | 135 45% J | 102 32% | 79 37% * | 111 37% | 18 39% * | 60 46% OQW | 32 30% * | 48 47% OQW* | 26 30% * | 37 33% * | 32 34% * | 50 37% * | 70 49% OQRSVW | 13 28% * | 29 28% * | 11 42% ** |
|--------------------------|------------|------------|------------|------------------|------------------|-----------------|-----------|------------|-----------------|------------|----------------|------------|----------------|------------------|----------------|-------------------|----------------|----------------|----------------|----------------|---------------------|----------------|----------------|-----------------|

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions (5%): A,B/C,D/E/F/G,H,I/J,K,L,M/N/O/P/Q/R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)

ColumnMeans (5%): A,B/C,D/E/F/G,H,I/J,K,L,M/N/O/P/Q/R/S/T/U/V/W/X Minimum Base: 30(**) Small Base: 100(*)

21-087515-10 - 9th March 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q15. Thinking about the treatment or treatments that you are waiting to start that relates to your chronic pain, for how long have you been waiting? - Summary

All awaiting treatment for chronic pain

| | Q15. Thinking about the treatment or treatments that you are waiting to start that relates to your chronic pain, for how long have you been waiting? | | | |
|-------------------------------|--|---------------------------|-----------------------------|--|
| | Surgery | Pain management programme | Opioid withdrawal programme | Other – i.e. I'm waiting for another type of treatment |
| | (A) | (B) | (C) | (D) |
| Unweighted base | 128 | 184 | 58 | 169 |
| Weighted base | 122 | 171 | 55 | 165 |
| For 1 month or less | 20 16% B* | 13 8% | 3 6% * | 33 20% 8C |
| For approximately 2-3 months | 15 12% * | 33 19% | 12 22% * | 37 22% A |
| For approximately 4-6 months | 21 17% * | 37 21% | 8 14% * | 31 19% |
| For approximately 7-12 months | 12 10% * | 25 14% | 9 17% * | 19 12% |
| For approximately 1-2 years | 21 17% * | 21 12% | 6 12% * | 21 13% |
| For approximately 2-3 years | 14 12% * | 16 10% | 6 12% * | 12 7% |
| For approximately 3-5 years | 6 5% * | 13 8% D | 4 8% D* | 2 1% |
| For more than 5 years | 11 9% * | 11 7% | 4 6% * | 8 5% |
| Don't know | 2 2% * | 3 2% | 2 4% | 3 2% |
| Prefer not to answer | 1 1% * | - - | - - | - - |

| | | | | |
|------------------------------|-----------------|----------------|-----------------|-----------|
| NET: For 1-2 years or longer | 52 43% D* | 61 36% | 21 38% * | 43 26% |
| NET: For 2-3 years or longer | 31 25% D* | 40 24% D | 14 26% D* | 21 13% |
| NET: For 3-5 years or longer | 16 13% D* | 24 14% D | 8 14% * | 10 6% |

uirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formatter used
ColumnsProportions (5%): A/B/C/D Minimum Base: 30(*) Small Base: 100(*)
ColumnsMeans (5%): A/B/C/D Minimum Base: 30(*) Small Base: 100(*)

21-087515-10 - 9th March 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q15. Thinking about the treatment or treatments that you are waiting to start that relates to your chronic pain, for how long have you been waiting? - Surgery

All awaiting treatment for chronic pain

| | | Gender | | | Age | | | | Social Grade | | | | Region | | | | | | | | | | | |
|-------------------------------|-----------|-----------|-----------|----------|----------|----------|----------|----------|--------------|----------|----------|----------|------------|------------|--------------------------|---------------|---------------|-----------------|------------|------------|----------------|----------|----------|------------------|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | A8 | C1 | C2 | DE | North East | North West | Yorkshire and Humberside | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 128 | 72 | 55 | 19 | 33 | 26 | 16 | 34 | 71 | 30 | 10 | 17 | 2 | 21 | 8 | 11 | 6 | 13 | 9 | 16 | 23 | 5 | 11 | 3 |
| Weighted base | 122 | 64 | 57 | 18 | 33 | 24 | 11 | 37 | 46 | 27 | 24 | 25 | 2 | 23 | 8 | 9 | 6 | 12 | 8 | 16 | 24 | 4 | 9 | 2 |
| For 1 month or less | 20 16% | 7 11% | 12 22% | 5 29% | 2 7% | 7 28% | * 5% | 5 13% | 8 18% | 4 16% | - 27% | 7 27% | - 15% | 4 15% | 1 15% | 1 15% | - 15% | 1 4% | 2 22% | 6 37% | 4 17% | - 6% | 1 34% | 1 2% |
| For approximately 2-3 months | 15 12% | 7 10% | 8 14% | 2 11% | 6 19% | 4 16% | * 4% | 2 5% | 6 13% | 3 12% | 4 16% | 1 6% | - 27% | 6 15% | - 27% | 1 11% | - 11% | 1 11% | 1 11% | - 13% | 3 21% | 1 14% | 1 14% | - 2% |
| For approximately 4-6 months | 21 17% | 7 11% | 14 25% | 6 34% | 5 15% | 2 9% | 3 29% | 3 13% | 6 14% | 5 18% | 4 16% | 6 23% | 2 76% | 3 13% | - 9% | 1 26% | 2 18% | 2 20% | 2 13% | 2 22% | 5 45% | 2 18% | 2 18% | - 2% |
| For approximately 7-12 months | 12 10% | 7 10% | 5 9% | 1 6% | 3 8% | 4 17% | 2 22% | 2 6% | 6 14% | 2 9% | - 13% | 3 13% | - 6% | 1 6% | 3 40% | 1 6% | 1 23% | 1 4% | 1 12% | 1 7% | 2 7% | 1 19% | 1 8% | - 2% |
| For approximately 1-2 years | 21 17% | 12 19% | 9 16% | * 3% | 9 26% | 3 13% | 2 23% | 7 18% | 6 12% | 5 19% | 8 32% | 3 11% | - 9% | 2 9% | 3 44% | 4 40% | * 8% | 6 49% | 1 12% | 1 8% | 1 4% | - 31% | 3 11% | - 2% |
| For approximately 2-3 years | 14 12% | 12 18% | 3 5% | 2 9% | - 4% | 1 4% | * 31% | 11 4% | 2 5% | 3 10% | 8 35% | 1 5% | * 24% | 4 16% | - 8% | 1 30% | 2 30% | - 16% | - 16% | 3 18% | 4 15% | 1 15% | * 5% | - 2% |
| For approximately 3-5 years | 6 5% | 5 8% | 1 1% | - 2% | - 5% | 1 3% | 1 8% | 2 6% | 3 7% | - 3% | - 7% | 1 5% | - 12% | 3 12% | - 12% | - 4% | - 4% | - 4% | - 4% | - 4% | 1 4% | - 6% | 1 6% | 2 66% |
| For more than 5 years | 11 9% | 8 13% | 1 2% | 1 7% | 6 18% | 1 6% | * 4% | 2 4% | 7 16% | 2 7% | - 5% | 1 5% | - 3% | 1 3% | - 11% | 1 11% | - 14% | 2 22% | 2 18% | 3 18% | 1 6% | - 11% | 1 11% | - 2% |
| Don't know | 2 2% | - 4% | 2 4% | - 2% | 1 2% | - 2% | - 4% | 1 4% | - 3% | 1 3% | - 5% | 1 5% | - 5% | - 5% | - 5% | - 13% | 1 13% | - 13% | - 13% | - 6% | 1 6% | - 6% | - 6% | - 6% |
| Prefer not to answer | 1 1% | - 2% | 1 2% | - 2% | - 2% | 1 4% | - 4% | - 4% | - 3% | 1 3% | - 3% | - 3% | - 3% | - 3% | - 3% | - 3% | - 3% | - 3% | - 3% | - 3% | 1 4% | - 4% | - 4% | - 4% |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|------------------------------|-----------|-----------|-----------|---------|-----------|----------|----------|-----------|-----------|-----------|-----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|----------|
| NET: For 1-2 years or longer | 52 43% | 37 58% | 14 24% | 3 5% | 16 19% | 6 26% | 4 40% | 22 60% | 19 41% | 10 39% | 16 68% | 7 26% | * 24% | 9 39% | 3 44% | 5 59% | 2 38% | 8 63% | 3 35% | 7 42% | 8 32% | 1 15% | 5 54% | 2 66% |
| NET: For 2-3 years or longer | 31 25% | 25 38% | 5 9% | 3 5% | 7 23% | 3 13% | 2 17% | 15 42% | 13 29% | 5 20% | 8 35% | 4 15% | * 24% | 7 30% | - 19% | 2 30% | 2 14% | 2 21% | 2 34% | 5 28% | 7 15% | 1 23% | 2 23% | 2 66% |
| NET: For 3-5 years or longer | 16 13% | 13 21% | 2 3% | 1 7% | 7 23% | 2 8% | 1 13% | 4 11% | 11 23% | 3 10% | - 10% | 3 10% | - 15% | 3 11% | - 11% | 1 14% | - 22% | 2 18% | 2 10% | 3 10% | 2 17% | - 17% | 2 17% | 2 66% |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions (5%): A,B/C,D,E,F,G,H,I/J,K/L,M,N/O,P/Q,R/S/T/U/V/W/X Minimum Base: 30 (**) Small Base: 100 (*)

ColumnMeans (5%): A,B/C,D,E,F,G,H,I/J,K/L,M,N/O,P/Q,R/S/T/U/V/W/X Minimum Base: 30 (**) Small Base: 100 (*)

21-087515-10 - 9th March 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q15. Thinking about the treatment or treatments that you are waiting to start that relates to your chronic pain, for how long have you been waiting? - Pain management programme

All awaiting treatment for chronic pain

| | | Gender | | | Age | | | | Social Grade | | | | Region | | | | | | | | | | | |
|-------------------------------|-------|--------|--------|-------|-------|-------|-------|-------|--------------|-----|-----|-----|------------|------------|----------------------|---------------|---------------|-----------------|------------|------------|----------------|-------|----------|------------------|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | A8 | C1 | C2 | DE | North East | North West | Yorkshire and Humber | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 184 | 104 | 80 | 37 | 54 | 47 | 14 | 32 | 99 | 38 | 14 | 33 | 10 | 20 | 12 | 13 | 14 | 16 | 11 | 21 | 44 | 6 | 15 | 2 |
| Weighted base | 171 | 93 | 78 | 33 | 54 | 35 | 13 | 37 | 58 | 36 | 30 | 47 | 11 | 22 | 12 | 13 | 13 | 15 | 9 | 18 | 35 | 7 | 14 | 1 |
| For 1 month or less | 13 | 9 | 4 | * | 4 | 1 | 1 | 7 | 4 | 4 | 3 | 1 | - | 2 | - | 1 | - | 1 | - | 3 | 6 | 1 | - | - |
| | 8% | 10% | 5% | 1% | 8% | 3% | 5% | 18% | 7% | 12% | 11% | 3% | - | 8% | - | 5% | - | 9% | - | 14% | 17% | 11% | - | - |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| For approximately 2-3 months | 33 | 17 | 16 | 12 | 9 | 7 | 2 | 3 | 13 | 6 | 7 | 7 | 4 | 2 | - | 1 | 3 | 3 | 3 | 7 | 8 | - | 1 | * |
| | 19% | 18% | 20% | 37% | 16% | 20% | 17% | 8% | 22% | 18% | 22% | 15% | 33% | 8% | - | 11% | 25% | 21% | 33% | 38% | 21% | - | 10% | 49% |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| For approximately 4-6 months | 37 | 18 | 18 | 7 | 7 | 8 | 2 | 13 | 10 | 9 | 6 | 12 | 4 | 3 | 4 | 4 | 4 | 4 | 2 | 3 | 8 | - | - | - |
| | 21% | 20% | 24% | 20% | 13% | 24% | 12% | 35% | 17% | 27% | 18% | 25% | 34% | 18% | 29% | 30% | 33% | 29% | 19% | 14% | 23% | - | - | - |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| For approximately 7-12 months | 25 | 11 | 14 | 3 | 10 | 2 | 5 | 5 | 8 | 6 | 3 | 8 | 3 | 6 | 4 | 2 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | * |
| | 14% | 12% | 18% | 11% | 18% | 6% | 35% | 13% | 14% | 16% | 11% | 16% | 23% | 29% | 32% | 12% | 4% | 6% | 5% | 21% | 6% | 21% | 4% | 51% |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| For approximately 1-2 years | 21 | 11 | 10 | 5 | 4 | 5 | 1 | 5 | 8 | 3 | 6 | 4 | - | 1 | 2 | 3 | 1 | 4 | 1 | - | 5 | - | 4 | - |
| | 12% | 12% | 13% | 16% | 8% | 13% | 9% | 15% | 14% | 8% | 19% | 9% | - | 5% | 21% | 19% | 11% | 24% | 6% | - | 14% | - | 30% | - |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| For approximately 2-3 years | 16 | 9 | 7 | 2 | 6 | 4 | 2 | 3 | 5 | 2 | 2 | 6 | 1 | * | 1 | 2 | 1 | - | - | - | 1 | 3 | 6 | - |
| | 10% | 10% | 9% | 5% | 10% | 12% | 12% | 9% | 9% | 7% | 7% | 13% | 10% | 2% | 12% | 11% | 11% | - | - | - | 4% | 47% | 40% | - |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| For approximately 3-5 years | 13 | 10 | 3 | 1 | 9 | 2 | - | 1 | 4 | 2 | 4 | 3 | - | 5 | 1 | 2 | - | 1 | 1 | 1 | 2 | - | 1 | - |
| | 8% | 11% | 3% | 4% | 17% | 6% | - | 2% | 8% | 6% | 12% | 6% | - | 21% | 6% | 11% | - | 6% | 13% | 7% | 6% | - | 4% | - |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| For more than 5 years | 11 | 7 | 4 | 1 | 5 | 5 | - | - | 5 | 2 | - | 4 | - | 1 | - | - | 2 | 1 | 2 | 1 | 3 | - | 1 | - |
| | 7% | 7% | 6% | 3% | 9% | 15% | - | - | 9% | 7% | - | 8% | - | 7% | - | - | 15% | 6% | 24% | 6% | 8% | - | 5% | - |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Don't know | 3 | 1 | 2 | 1 | 1 | - | 1 | - | 1 | - | - | 2 | - | 1 | - | - | - | - | - | - | - | 1 | 1 | - |
| | 2% | 1% | 3% | 3% | 1% | - | 11% | - | 1% | - | - | 5% | - | 3% | - | - | - | - | - | - | - | 21% | 7% | - |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| Prefer not to answer | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| | | | | | | | | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|------------------------------|-----------|-----------|-----------|----------|-----------|-----------|----------|----------|-----------|-----------|-----------|-----------|----------|----------|----------|----------|----------|----------|----------|----------|-----------|----------|-----------|--------|
| NET: For 1-2 years or longer | 61 36% | 37 40% | 24 31% | 9 28% | 24 44% | 16 46% | 3 20% | 9 26% | 23 39% | 10 28% | 12 38% | 17 36% | 1 10% | 8 34% | 5 39% | 6 42% | 5 37% | 5 35% | 4 43% | 2 13% | 11 32% | 3 47% | 11 79% | - - |
| NET: For 2-3 years or longer | 40 24% | 26 28% | 14 18% | 4 12% | 19 36% | 11 33% | 2 12% | 4 11% | 15 26% | 7 20% | 6 19% | 13 27% | 1 10% | 7 30% | 2 18% | 3 23% | 3 26% | 2 11% | 3 37% | 2 13% | 7 19% | 3 47% | 7 49% | - - |
| NET: For 3-5 years or longer | 24 14% | 17 18% | 7 9% | 2 7% | 14 26% | 7 21% | - 2% | 1 2% | 9 16% | 4 13% | 4 12% | 6 14% | - - | 6 27% | 1 6% | 2 11% | 2 15% | 2 11% | 3 37% | 2 13% | 5 15% | - - | 1 10% | - - |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions (5%): A,B/C,D,E,F,G,H,I/J,K/L,M,N/O,P/Q,R/S/T/U/V/W/X Minimum Base: 30 (**) Small Base: 100 (*)

ColumnMeans (5%): A,B/C,D,E,F,G,H,I/J,K/L,M,N/O,P/Q,R/S/T/U/V/W/X Minimum Base: 30 (**) Small Base: 100 (*)

21-087515-10 - 9th MArch 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q15. Thinking about the treatment or treatments that you are waiting to start that relates to your chronic pain, for how long have you been waiting? - Opioid withdrawal programme

All awaiting treatment for chronic pain

| | | Gender | | | Age | | | | | Social Grade | | | | | Region | | | | | | | | | |
|-------------------------------|-----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|-------------------|-------------------|---|-------------------------|-------------------------|---------------------------|----------------------|-------------------|--------------------------|----------------|-----------------|----------------------------|
| | Total (A) | Male (B) | Female (C) | 16-24 (D) | 25-34 (E) | 35-44 (F) | 45-54 (G) | 55-75 (H) | A8 (I) | C1 (J) | C2 (K) | DE (L) | North East (M) | North West (N) | Yorkshire and Humberts de (O) | West Midlands (P) | East Midlands (Q) | East of England (R) | South West (S) | South East (T) | Greater London (U) | Wales (V) | Scotland (W) | Northern Ireland (X) |
| Unweighted base | 58 | 35 | 23 | 20 | 17 | 14 | 3 | 4 | 33 | 10 | 8 | 7 | 3 | 4 | 4 | 5 | 2 | 2 | 5 | 8 | 16 | 4 | 2 | 3 |
| Weighted base | 55 | 29 | 26 | 19 | 16 | 11 | 2 | 6 | 20 | 8 | 17 | 9 | 5 | 3 | 3 | 6 | 3 | 2 | 4 | 7 | 13 | 4 | 1 | 3 |
| For 1 month or less | 3 6% ** | 2 6% ** | 1 5% ** | 2 8% ** | 1 9% ** | - - ** | - - ** | - - ** | 1 4% ** | 2 27% ** | - - ** | - - ** | 1 13% ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | 1 12% ** | 1 6% ** | 1 18% ** | - - ** | - - ** |
| For approximately 2-3 months | 12 22% ** | 7 25% ** | 5 18% ** | 5 28% ** | 1 6% ** | 5 44% ** | 1 33% ** | - - ** | 7 34% ** | - - ** | 3 16% ** | 2 26% ** | - - ** | * 13% ** | 2 67% ** | 3 43% ** | - - ** | - - ** | * 14% ** | 2 28% ** | 4 29% ** | - - ** | 1 46% ** | - - ** |
| For approximately 4-6 months | 8 14% ** | 4 15% ** | 4 14% ** | 3 14% ** | 4 24% ** | - - ** | - - ** | 1 19% ** | 3 15% ** | 3 31% ** | 2 13% ** | - - ** | - - ** | 1 21% ** | * 16% ** | - - ** | 1 39% ** | - - ** | - - ** | - - ** | 3 19% ** | 1 18% ** | - - ** | 2 67% ** |
| For approximately 7-12 months | 9 17% ** | 4 12% ** | 6 22% ** | 3 16% ** | 3 4% ** | 1 13% ** | 2 67% ** | 3 48% ** | 3 16% ** | 2 23% ** | 4 24% ** | - - ** | 2 41% ** | - - ** | * 17% ** | 1 16% ** | - - ** | - - ** | 1 16% ** | 2 34% ** | 1 7% ** | 1 13% ** | 1 54% ** | 1 20% ** |
| For approximately 1-2 years | 6 12% ** | 2 7% ** | 4 17% ** | 2 11% ** | 4 27% ** | - - ** | - - ** | - - ** | 1 4% ** | - - ** | 2 10% ** | 4 43% ** | - - ** | 2 65% ** | - - ** | 1 16% ** | - - ** | - - ** | - - ** | - - ** | 3 22% ** | - - ** | - - ** | * 13% ** |
| For approximately 2-3 years | 6 12% ** | 4 13% ** | 3 11% ** | 4 19% ** | 2 14% ** | 1 5% ** | - - ** | - - ** | 3 14% ** | 1 9% ** | - - ** | 3 31% ** | - - ** | - - ** | - - ** | 2 25% ** | - - ** | 1 51% ** | 2 58% ** | 1 17% ** | 1 5% ** | - - ** | - - ** | - - ** |
| For approximately 3-5 years | 4 8% ** | 4 15% ** | - - ** | 1 5% ** | - - ** | 3 30% ** | - - ** | - - ** | 2 10% ** | - - ** | 2 14% ** | - - ** | 2 46% ** | - - ** | - - ** | - - ** | - - ** | - - ** | * 13% ** | - - ** | 2 11% ** | - - ** | - - ** | - - ** |
| For more than 5 years | 4 6% ** | 2 7% ** | 1 6% ** | - - ** | 1 4% ** | 1 7% ** | - - ** | 2 32% ** | 1 3% ** | 1 10% ** | 2 12% ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | 1 49% ** | - - ** | 1 8% ** | - - ** | 2 51% ** | - - ** | - - ** |
| Don't know | 2 4% ** | - - ** | 2 8% ** | - - ** | 2 12% ** | - - ** | - - ** | - - ** | - - ** | - - ** | 2 12% ** | - - ** | - - ** | - - ** | - - ** | - - ** | 2 61% ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** |
| Prefer not to answer | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** | - - ** |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|------------------------------|-----------------|-----------------|----------------|----------------|----------------|----------------|--------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|--------------|----------------|--------------|-----------------|----------------|----------------|----------------|----------------|--------------|----------------|
| NET: For 1-2 years or longer | 21 38% ** | 12 42% ** | 9 33% ** | 7 34% ** | 7 45% ** | 5 43% ** | - - ** | 2 32% ** | 6 32% ** | 2 19% ** | 6 35% ** | 7 74% ** | 2 46% ** | 2 65% ** | - - ** | 3 41% ** | - - ** | 2 100% ** | 3 71% ** | 2 26% ** | 5 39% ** | 2 51% ** | - - ** | * 13% ** |
| NET: For 2-3 years or longer | 14 26% ** | 10 35% ** | 4 16% ** | 4 24% ** | 3 18% ** | 5 43% ** | - - ** | 2 32% ** | 5 27% ** | 2 19% ** | 4 26% ** | 3 31% ** | 2 46% ** | - - ** | - - ** | 2 25% ** | - - ** | 2 100% ** | 3 71% ** | 2 26% ** | 2 16% ** | 2 51% ** | - - ** | - - ** |
| NET: For 3-5 years or longer | 8 14% ** | 6 22% ** | 1 6% ** | 1 5% ** | 1 4% ** | 4 37% ** | - - ** | 2 32% ** | 3 13% ** | 1 10% ** | 4 26% ** | - - ** | 2 46% ** | - - ** | - - ** | - - ** | - - ** | 1 49% ** | * 13% ** | 1 8% ** | 2 11% ** | 2 51% ** | - - ** | - - ** |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions (5%): A,B/C,D,E,F/G,H,I/J,K/L,M,N/O,P/Q,R/S/T/U,V/W/X Minimum Base: 30 (**) Small Base: 100 (*)

ColumnMeans (5%): A,B/C,D,E,F/G,H,I/J,K/L,M,N/O,P/Q,R/S/T/U,V/W/X Minimum Base: 30 (**) Small Base: 100 (*)

21-087515-10 - 9th March 2022 - 14th March 2022

PUBLIC

BBC - Chronic Pain Survey

All UK adults aged 16-75

Q15. Thinking about the treatment or treatments that you are waiting to start that relates to your chronic pain, for how long have you been waiting? - Other – i.e. I'm waiting for another type of treatment

All awaiting treatment for chronic pain

| | | Gender | | | Age | | | | Social Grade | | | | Region | | | | | | | | | | | |
|-------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|-----------|-----------------|----------------|----------------|-----------------|----------------|---------------|----------------------|---------------|---------------|-----------------|------------|------------|----------------|----------|----------|------------------|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | A8 | C1 | C2 | DE | North East | North West | Yorkshire and Humber | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) |
| Unweighted base | 169 | 71 | 95 | 22 | 31 | 23 | 27 | 66 | 74 | 47 | 10 | 38 | 3 | 21 | 13 | 22 | 10 | 17 | 14 | 25 | 24 | 7 | 7 | 6 |
| Weighted base | 165 | 65 | 97 | 22 | 26 | 23 | 24 | 70 | 47 | 43 | 21 | 54 | 3 | 22 | 15 | 23 | 10 | 15 | 15 | 25 | 21 | 4 | 6 | 5 |
| For 1 month or less | 33 20% * | 12 18% * | 21 22% * | 5 22% ** | 3 11% ** | 7 28% ** | 5 22% ** | 13 19% | 6 12% * | 11 25% * | 4 18% ** | 12 23% * | 2 75% ** | 4 19% | 3 23% | 3 14% | 2 24% | 3 20% | 2 13% | 4 17% | 6 28% | 1 17% | 1 11% | 1 19% |
| For approximately 2-3 months | 37 22% * | 16 25% * | 20 21% * | 2 8% ** | 1 5% ** | 7 30% ** | 9 39% | 17 24% | 6 13% * | 11 26% * | 5 24% ** | 14 26% * | 1 25% ** | 10 45% | 3 19% | 2 10% | 3 32% | 5 33% | 4 26% | 3 11% | 4 19% | 1 29% | * 9% | - ** |
| For approximately 4-6 months | 31 19% * | 7 11% * | 23 23% * | 6 26% ** | 4 17% ** | 2 10% ** | 3 13% ** | 16 22% | 7 15% * | 9 21% ** | 5 23% ** | 10 18% * | - ** | 1 5% | 4 24% | 9 37% | 1 9% | 2 10% | 2 17% | 5 21% | 4 20% | - ** | 3 51% | 1 14% |
| For approximately 7-12 months | 19 12% * | 8 12% * | 11 11% * | 3 14% ** | 6 23% ** | 1 3% ** | 2 9% ** | 7 10% | 9 19% L* | 7 15% L* | 4 18% ** | - ** | - ** | 3 16% | 2 12% | 2 10% | 2 17% | 2 10% | 2 10% | 5 21% | 1 4% | 1 12% | - ** | - ** |
| For approximately 1-2 years | 21 13% * | 9 14% * | 11 11% * | 2 7% ** | 5 20% ** | 2 8% ** | 2 8% ** | 11 15% | 7 15% * | 4 8% ** | 2 8% ** | 9 16% * | - ** | 3 13% | 2 10% | 3 13% | 1 5% | 3 20% | 2 13% | 2 9% | 2 11% | - ** | 1 14% | 3 53% |
| For approximately 2-3 years | 12 7% * | 7 10% * | 5 5% ** | 2 9% ** | 4 16% ** | 2 7% ** | 1 3% ** | 3 4% | 9 20% JL* | 1 2% * | - ** | 2 3% ** | - ** | - ** | 2 ** | 1 ** | - ** | - ** | 1 8% | 3 10% | 4 18% | 1 12% | 1 15% | - ** |
| For approximately 3-5 years | 2 1% * | 1 1% * | 1 1% ** | - ** | 1 4% ** | - ** | - ** | 1 1% | 1 2% * | 1 2% ** | - ** | - ** | - ** | - ** | - ** | - ** | - ** | - ** | - ** | 1 2% | - ** | 1 12% | - ** | 1 14% |
| For more than 5 years | 8 5% * | 4 7% * | 3 3% ** | 3 14% ** | - ** | 3 13% ** | - ** | 1 2% | - ** | - ** | 2 9% ** | 6 11% JL* | - ** | - ** | - ** | 1 6% | 1 12% | 1 7% | 2 13% | 2 8% | - ** | - ** | - ** | - ** |
| Don't know | 3 2% * | 1 2% * | 1 1% ** | - ** | 1 2% ** | - ** | 1 5% ** | 1 1% | 1 3% * | - ** | - ** | 1 2% ** | - ** | 1 3% ** | - ** | 1 5% ** | - ** | - ** | - ** | - ** | - ** | 1 17% | - ** | - ** |
| Prefer not to answer | - - | - * | - * | - ** | - ** | - ** | - ** | - - | - * | - * | - ** | - * | - ** | - ** | - ** | - ** | - ** | - ** | - ** | - ** | - ** | - ** | - ** | - ** |

| | | | | | | | | | | | | | | | | | | | | | | | | |
|------------------------------|-----------|----------------|-----------------|----------------|-----------------|----------------|----------------|-----------|-----------------|---------------|----------------|----------------|---------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| NET: For 1-2 years or longer | 43 26% | 21 32% * | 20 21% * | 7 30% ** | 11 41% ** | 7 29% ** | 3 11% ** | 16 23% | 17 37% J* | 5 12% * | 4 17% ** | 16 30% * | - ** | 3 13% ** | 3 22% ** | 6 24% ** | 2 18% ** | 4 27% ** | 5 34% ** | 7 29% ** | 6 29% ** | 1 24% ** | 2 29% ** | 4 67% ** |
| NET: For 2-3 years or longer | 21 13% | 12 18% * | 10 10% ** | 5 23% ** | 5 21% ** | 5 21% ** | 1 3% ** | 5 8% | 10 22% J* | 2 4% ** | 2 9% ** | 7 14% * | - ** | - ** | 2 11% ** | 3 12% ** | 1 7% ** | 1 21% ** | 3 20% ** | 5 18% ** | 4 24% ** | 1 24% ** | 1 15% ** | 1 14% ** |
| NET: For 3-5 years or longer | 10 6% | 5 8% * | 4 5% ** | 3 14% ** | 1 4% ** | 3 13% ** | - ** | 2 3% | 1 2% * | 1 2% ** | 2 9% ** | 6 11% * | - ** | - ** | - ** | 1 6% ** | 1 12% ** | 1 7% ** | 2 13% ** | 3 10% ** | - ** | 1 12% ** | - ** | 1 14% ** |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlap formulae used

ColumnProportions (5%): A,B/C,D,E,F,G,H,I/J,K/L,M,N/O,P/Q/R/S/T/U/V/W/X Minimum Base: 30 (**) Small Base: 100 (*)

ColumnMeans (5%): A,B/C,D,E,F,G,H,I/J,K/L,M,N/O,P/Q/R/S/T/U/V/W/X Minimum Base: 30 (**) Small Base: 100 (*)

21-087515-10 - 9th March 2022 - 14th March 2022
PUBLIC
BRC - Chronic Pain Survey
All UK adults aged 16-75

Sample Profile
All adults aged 16-75 in the UK

| | Gender | | | Age | | | | | Social Grade | | | | Region | | | | | | | | | | | | | |
|--------------------------|--------|------|--------|-------|-------|-------|-------|-------|--------------|------|------|------|------------|------------|--------------------------|---------------|---------------|-----------------|------------|------------|----------------|-------|----------|------------------|-----|--|
| | Total | Male | Female | 16-24 | 25-34 | 35-44 | 45-54 | 55-75 | A8 | C1 | C2 | DE | North East | North West | Yorkshire and Humberside | West Midlands | East Midlands | East of England | South West | South East | Greater London | Wales | Scotland | Northern Ireland | | |
| | (A) | (B) | (C) | (D) | (E) | (F) | (G) | (H) | (I) | (J) | (K) | (L) | (M) | (N) | (O) | (P) | (Q) | (R) | (S) | (T) | (U) | (V) | (W) | (X) | | |
| Unweighted base | 4435 | 2127 | 2280 | 673 | 776 | 793 | 861 | 1332 | 1948 | 1369 | 415 | 703 | 184 | 500 | 376 | 396 | 325 | 416 | 359 | 564 | 601 | 215 | 379 | 120 | | |
| | 2183 | 2183 | 2224 | 661 | 817 | 757 | 814 | 1386 | 1182 | 1301 | 950 | 1002 | 176 | 485 | 366 | 389 | 323 | 410 | 373 | 603 | 605 | 209 | 374 | 124 | | |
| Male | 2183 | 2183 | - | 333 | 407 | 373 | 401 | 670 | 599 | 601 | 520 | 463 | 88 | 232 | 159 | 171 | 152 | 189 | 164 | 294 | 358 | 109 | 208 | 65 | | |
| | 49% | 100% | - | 50% | 50% | 49% | 49% | 48% | 51% | 46% | 55% | 48% | 50% | 48% | 43% | 44% | 47% | 46% | 44% | 49% | 53% | 52% | 50% | 52% | | |
| | | C | | | | | | | JL | | JL | | | | | | | | | NONREGIST | | | | * | | |
| Female | 2224 | - | 2224 | 320 | 400 | 378 | 411 | 714 | 570 | 694 | 427 | 533 | 88 | 253 | 204 | 211 | 169 | 220 | 207 | 307 | 249 | 97 | 161 | 58 | | |
| | 50% | - | 100% | 48% | 49% | 50% | 51% | 52% | 48% | 53% | 43% | 53% | 50% | 52% | 56% | 54% | 52% | 54% | 56% | 51% | 41% | 47% | 43% | 47% | | |
| | | B | | | | | | | JL | | JL | | | UW | UW | UW | UW | UW | UW | UW | | | | * | | |
| 16-24 | 661 | 333 | 320 | 661 | - | - | - | - | 142 | 123 | 162 | 234 | 24 | 70 | 52 | 54 | 42 | 59 | 44 | 84 | 134 | 22 | 51 | 25 | | |
| | 15% | 15% | 14% | 100% | - | - | - | - | 12% | 9% | 17% | 23% | 14% | 14% | 14% | 14% | 13% | 14% | 12% | 14% | 22% | 10% | 14% | 20% | | |
| | | | | DEGH | | | | | F | | | | | U | | | | | | MINOREGIST | | | | SW* | | |
| 25-34 | 817 | 407 | 400 | - | 817 | - | - | - | 236 | 240 | 166 | 175 | 24 | 91 | 57 | 90 | 60 | 58 | 52 | 86 | 158 | 38 | 76 | 28 | | |
| | 18% | 19% | 18% | - | 100% | - | - | - | 20% | 18% | 17% | 17% | 14% | 19% | 15% | 23% | 19% | 14% | 14% | 24% | 18% | 20% | 22% | 22% | | |
| | | | | | DEGH | | | | | | | | | | | MOORET | | | | MINOREGIST | | | | * | | |
| 35-44 | 757 | 373 | 378 | - | - | 757 | - | - | 248 | 216 | 141 | 152 | 28 | 68 | 49 | 52 | 47 | 83 | 69 | 123 | 112 | 44 | 64 | 19 | | |
| | 17% | 17% | 17% | - | - | 100% | - | - | 21% | 17% | 13% | 13% | 10% | 14% | 13% | 13% | 13% | 20% | 19% | 20% | 18% | 21% | 17% | 15% | | |
| | | | | | | DEGH | | | JL | | | | | | | | | NOP | | NOP | | | | * | | |
| 45-54 | 814 | 401 | 411 | - | - | - | 814 | - | 234 | 259 | 162 | 159 | 26 | 94 | 64 | 86 | 66 | 82 | 72 | 110 | 87 | 39 | 68 | 19 | | |
| | 18% | 18% | 18% | - | - | - | 100% | - | 20% | 20% | 17% | 16% | 15% | 19% | 17% | 22% | 20% | 20% | 19% | 18% | 14% | 19% | 18% | 16% | | |
| | | | | | | | DEGH | | | | | | | U | | | | | | | | | | * | | |
| 55-75 | 1386 | 670 | 714 | - | - | - | - | - | 1386 | 323 | 462 | 320 | 282 | 74 | 163 | 144 | 107 | 107 | 128 | 136 | 300 | 113 | 66 | 115 | 33 | |
| | 31% | 31% | 32% | - | - | - | - | - | 100% | 27% | 36% | 34% | 28% | 42% | 34% | 39% | 28% | 33% | 31% | 36% | 33% | 19% | 32% | 31% | 26% | |
| | | | | | | | | | DEFG | | | | | PRUWV | U | PRUWV | U | U | U | PU | U | | U | U | * | |
| A8 | 1182 | 599 | 570 | 142 | 236 | 248 | 234 | 323 | 1182 | - | - | - | 37 | 111 | 94 | 90 | 83 | 107 | 100 | 185 | 191 | 61 | 93 | 29 | | |
| | 27% | 27% | 26% | 21% | 29% | 30% | 29% | 23% | 100% | - | - | - | 21% | 23% | 26% | 23% | 26% | 26% | 27% | 31% | 32% | 29% | 25% | 24% | | |
| | | | | DE | DE | DE | DE | HL | | | | | | | | | | | | EMW | EMW | | | * | | |
| C1 | 1301 | 601 | 694 | 123 | 240 | 216 | 259 | 462 | - | 1301 | - | - | 51 | 155 | 98 | 118 | 98 | 124 | 106 | 184 | 164 | 65 | 105 | 32 | | |
| | 29% | 28% | 31% | 31% | 32% | 33% | 33% | 100% | - | 100% | - | - | 29% | 32% | 27% | 30% | 30% | 30% | 28% | 30% | 27% | 31% | 28% | 26% | | |
| | | | B | | D | D | D | DE | HL | | | | | | | | | | | | | | | * | | |
| C2 | 950 | 520 | 427 | 162 | 166 | 141 | 162 | 320 | - | - | 950 | - | 36 | 109 | 75 | 95 | 63 | 89 | 79 | 127 | 114 | 41 | 85 | 39 | | |
| | 21% | 24% | 19% | 24% | 20% | 19% | 20% | 23% | - | - | 100% | - | 30% | 23% | 20% | 14% | 19% | 22% | 21% | 31% | 19% | 20% | 23% | 31% | | |
| | | C | F | | | | F | | HL | | | | | | | | | | | | | | | DEGH* | | |
| DE | 1002 | 463 | 533 | 234 | 175 | 152 | 159 | 282 | - | - | 1002 | 52 | 110 | 98 | 86 | 80 | 90 | 88 | 107 | 136 | 41 | 90 | 24 | | | |
| | 23% | 21% | 24% | 35% | 21% | 20% | 20% | 20% | - | - | 100% | 29% | 23% | 27% | 23% | 22% | 25% | 22% | 24% | 18% | 22% | 20% | 24% | 19% | | |
| | | | DEGH | | | | | | | | UK | TV | | | | | | F | | | | | F | * | | |
| North East | 176 | 88 | 88 | 24 | 24 | 28 | 36 | 74 | 37 | 51 | 36 | 52 | 17% | - | - | - | - | - | - | - | - | - | - | - | | |
| | 4% | 4% | 4% | 3% | 3% | 4% | 3% | 5% | 3% | 4% | 3% | 4% | 100% | - | - | - | - | - | - | - | - | - | - | * | | |
| | | | | | | | | EG | | | | | I | NONREGIST | | | | | | | | | | * | | |
| North West | 485 | 232 | 253 | 70 | 91 | 68 | 94 | 163 | 111 | 155 | 109 | 110 | - | 485 | - | - | - | - | - | - | - | - | - | - | | |
| | 11% | 11% | 11% | 11% | 11% | 9% | 12% | 12% | 11% | 12% | 11% | 11% | - | 100% | - | - | - | - | - | - | - | - | - | - | | |
| | | | | | | | | | I | | | | | MINOREGIST | | | | | | | | | | * | | |
| Yorkshire and Humberside | 366 | 159 | 204 | 52 | 57 | 49 | 64 | 144 | 94 | 98 | 75 | 98 | - | - | 366 | - | - | - | - | - | - | - | - | - | | |
| | 8% | 7% | 9% | 8% | 7% | 6% | 8% | 10% | 8% | 8% | 8% | 12% | - | - | 100% | - | - | - | - | - | - | - | - | * | | |
| | | B | | | | | EF | | | | | | | | MINOREGIST | | | | | | | | | * | | |
| West Midlands | 389 | 171 | 211 | 54 | 90 | 52 | 86 | 107 | 90 | 118 | 95 | 86 | - | - | - | 389 | - | - | - | - | - | - | - | - | | |
| | 9% | 8% | 9% | 8% | 11% | 7% | 11% | 8% | 8% | 9% | 10% | 9% | - | - | - | 100% | - | - | - | - | - | - | - | * | | |
| | | | | FH | | | FI | | | | | | | | | MINOREGIST | | | | | | | | * | | |
| East Midlands | 323 | 152 | 169 | 42 | 60 | 47 | 66 | 107 | 83 | 98 | 63 | 80 | - | - | - | - | 323 | - | - | - | - | - | - | - | | |
| | 7% | 7% | 8% | 6% | 7% | 6% | 8% | 8% | 7% | 8% | 7% | 8% | - | - | - | - | 100% | - | - | - | - | - | - | * | | |
| | | | | | | | | | | | | | | | | | MINOREGIST | | | | | | | * | | |
| East of England | 410 | 189 | 220 | 59 | 58 | 83 | 82 | 128 | 107 | 124 | 89 | 90 | - | - | - | - | - | 410 | - | - | - | - | - | - | | |
| | 9% | 9% | 10% | 9% | 7% | 10% | 9% | 10% | 9% | 10% | 9% | 9% | - | - | - | - | - | 100% | - | - | - | - | - | * | | |
| | | | | | | E | | | | | | | | | | | | MINOREGIST | | | | | | * | | |
| South West | 373 | 164 | 207 | 44 | 52 | 69 | 72 | 136 | 100 | 106 | 79 | 88 | - | - | - | - | - | - | 373 | - | - | - | - | - | | |
| | 8% | 7% | 9% | 7% | 6% | 9% | 9% | 10% | 8% | 8% | 8% | 9% | - | - | - | - | - | - | 100% | - | - | - | - | * | | |
| | | | | | | | | DE | | | | | | | | | | | MINOREGIST | | | | | * | | |
| South East | 603 | 294 | 307 | 84 | 86 | 123 | 110 | 200 | 185 | 184 | 127 | 107 | - | - | - | - | - | - | - | 603 | - | - | - | - | | |
| | 14% | 13% | 14% | 13% | 12% | 16% | 14% | 14% | 14% | 14% | 13% | 11% | - | - | - | - | - | - | - | 100% | - | - | - | * | | |
| | | | | | | E | E | L | L | | | | | | | | | | | MINOREGIST | | | | * | | |
| Greater London | 605 | 352 | 249 | 134 | 158 | 112 | 87 | 113 | 191 | 164 | 114 | 136 | - | - | - | - | - | - | - | 605 | - | - | - | - | | |
| | 14% | 16% | 11% | 20% | 19% | 15% | 11% | 8% | 16% | 13% | 12% | 14% | - | - | - | - | - | - | - | 100% | - | - | - | * | | |
| | | C | | FGH | FGH | GH | | JL | | | | | | | | | | | | MINOREGIST | | | | * | | |
| Wales | 209 | 109 | 97 | 22 | 38 | 44 | 39 | 66 | 61 | 65 | 41 | 41 | - | - | - | - | - | - | - | - | 209 | - | - | - | | |
| | 5% | 5% | 4% | 3% | 5% | 6% | 5% | 5% | 5% | 5% | 4% | 4% | - | - | - | - | - | - | - | - | 100% | - | - | * | | |
| | | | | | D | | | | | | | | | | | | | | | MINOREGIST | | | | * | | |
| Scotland | 374 | 208 | 161 | 51 | 76 | 64 | 68 | 115 | 93 | 105 | 85 | 90 | - | - | - | - | - | - | - | - | - | - | 374 | - | | |
| | 8% | 10% | 7% | 8% | 9% | 8% | 8% | 8% | 8% | 8% | 9% | 9% | - | - | - | - | - | - | - | - | - | - | 100% | * | | |
| | | C | | | | | | | | | | | | | | | | | | MINOREGIST | | | | MINOREGIST | | |
| Northern Ireland | 124 | 65 | 58 | 25 | 28 | 19 | 19 | 33 | 29 | 32 | 39 | 24 | - | - | - | - | - | - | - | - | - | - | - | 124 | | |
| | 3% | 3% | 3% | 4% | 3% | 3% | 3% | 2% | 2% | 2% | 4% | 2% | - | - | - | - | - | - | - | - | - | - | - | 100% | | |
| | | | | | | | | | | | | | | | | | | | | MINOREGIST | | | | MINOREGIST | | |
| | | | | | | | | | | | | | | | | | | | | | | | | SW* | | |

This work was carried out in accordance with the requirements of the international quality standard for market research, ISO 20252 and with the Ipsos MORI Terms and Conditions.

Overlay formulae used

ColumnOperations (DN) A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X Minimum Base: 30(**) Small Base: 100(*)

ColumnMeans (DN) A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X Minimum Base: 30(**) Small Base: 100(*)